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Abstract 
 
 The HIV epidemic persists in many parts of the world, with the majority of new infections 
occurring through the female genital tract (FGT). The permissiveness of the genital mucosa to 
HIV is modulated by the integrity of the epithelial barrier, the presence of pro-inflammatory 
cytokines, and the frequency of CCR5+CD4+ T cell targets. Here we focus on two biological 
perturbations: endogenous alterations in cervicovaginal bacteria and exogenous injectable 
progestin-only contraceptives (IPCs). We examine their effects on the genital mucosal 
environment and their link to HIV susceptibility in a cohort of young South African women. 
 We first sought to determine how genital microbiota modulate host inflammatory 
responses. The existing paradigm is that vaginal monocolonization by Lactobacillus is normal, 
and encroachment by other bacteria is pathologic. By characterizing cervicovaginal bacterial 
communities in 94 South African women using 16S rRNA and shotgun sequencing, we found 
that the majority of participants had low Lactobacillus abundance and high ecological diversity. 
One diverse Prevotella-containing community type strongly correlated with increased 
concentrations of multiple genital pro-inflammatory cytokines in vivo. We found that these 
cytokines were produced by epithelial cells and antigen presenting cells via different bacterial 
sensing mechanisms. Our results identify specific bacterial species that alter the inflammatory 
state of the FGT and may more broadly impact reproductive health in women. 
 We also investigated the immunological effects of IPCs, the most common form of birth 
control in sub-Saharan Africa. Although highly effective as a contraceptive, IPCs are 
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controversially associated with increased HIV susceptibility by an unclear mechanism. We found 
that IPC users had a 5.5-fold higher risk of acquiring HIV than women not using family planning 
(p=0.0031, 95% CI: 1.733 – 16.80). Phenotypic cellular analysis revealed that IPC users also 
had a significantly higher frequency of activated HIV target cells in the cervix. Since the 
availability of target cells in the genital mucosa enables early viral replication, recruitment or 
retention of these cells by IPCs may explain the observed increased HIV acquisition rates. 
Furthermore, IPC use was not associated with differences in genital cytokine levels, indicating 
that cervicovaginal bacteria and exogenous progesterone increase HIV susceptibility by unique 
pathways. 
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Chapter 1: Introduction 
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Epidemiology of HIV 
 The epidemiology of the HIV epidemic has changed dramatically since the first cases of 
Acquired Immune Deficiency Syndrome (AIDS) were reported in 1981. At that time, clinicians in 
New York City and San Francisco noticed a disturbing increase in previously healthy 
homosexual men presenting with advanced opportunistic infections. This mysterious disease 
with no identifiable cause was initially called “Gay-related immunodeficiency” (GRID) and “the 
4H disease,” as it presented primarily in Haitians, homosexuals, hemophiliacs, and heroin 
users. Eventually, it was renamed AIDS (2). Today in 2015, 35 million men, women, and 
children around the world are living with HIV. While men who have sex with men continue to be 
19 times more likely to be HIV-positive than the general population (3), 15% of people living with 
HIV are women between the ages of 15-24 and 80% of those young women live in sub-Saharan 
Africa (Figure 1.1) (4).  
 
Figure 1.1 Geographic differences in populations living with HIV. Note that the majority of HIV+ 
young women are in sub-Saharan Africa. Men who have sex with men is abbreviated as MSM. Adapted 
from the UNAIDS 2014 Gap Report (5). 
The number of new infections is decreasing globally, but the incidence rate amongst 18-
23 year old women in Durban, South Africa remains around a staggering 7%. The vulnerability 
of women is exemplified by the rural community of Vulindlela, South Africa where the 
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prevalence of HIV in girls younger than 14 years is 2% but increases to approximately 50% in 
23-24 year old pregnant women (6). It is hard to reconcile this astonishingly high HIV 
prevalence with estimates of the risk of transmission from an infected man to uninfected women 
around 0.19% per unprotected sex act (95% CI: 0.0010-0.0037) (7). One interpretation is that 
particular young women have risk factors that are not captured in the stable serodiscordant 
couple cohorts that yield such transmission risk estimates. To understand those risk factors, we 
must improve our understanding of the female genital tract (FGT), the most common site of first 
exposure to HIV in women. 
Brief overview of HIV virology 
 HIV may very well be the best studied pathogen in the world and a phenomenal amount 
of detail is known about its structure and life cycle. Briefly, HIV is a retrovirus that comes in two 
forms: HIV-1 and HIV-2. HIV-2 is mostly found in West Africa and has a lower probability of 
being transmitted and progressing to AIDS than HIV-1 (8). HIV-1 is the predominant form 
worldwide and is comprised of three groups, with nearly 98% of circulating viruses belonging to 
Group M (9); in this thesis HIV-1 will be referred to simply as HIV. Within Group M, Subtype C of 
HIV-1 is the most common form of HIV in Southern Africa and comprises about 60% of HIV 
cases worldwide, and Subtype B is the dominant form in Europe and the U.S. (10). 
 Each HIV virion has a capsid containing: two identical copies of its full-length, 9,749 
nucleotide-long RNA genome; reverse transcriptase that lacks 3’ exonuclease proofreading 
activity, leading to about one mutation arising per replication cycle; and integrase (11). Within 
the viral envelope, which the virion acquires when budding from its host cell, is a protease that 
is required for the virion to mature and become infective (12). On the surface of the viral 
envelope are around seven heavily glycosylated trimeric spikes of gp120 with gp41, which 
determine the target cell tropism by enabling the virus to bind to CD4+ and either the CCR5 or 
CXCR4 coreceptor. Once HIV fuses to its target cell, the single-stranded RNA genome is 
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reverse transcribed into cDNA, transported into the nucleus, and integrated into the host 
genome via the HIV integrase protein. The virus can remain latently integrated in the host 
genome, or it can actively produce copies of itself by transcribing and translating its viral genes 
and proteins, which translocate to the cell surface, assemble, and bud off as immature virions 
(13). 
 The HIV virion that crosses the genital mucosal barrier to establish a systemic infection 
in a new host consistently utilizes the CCR5 coreceptor rather than CXCR4 (14). As the focus of 
this thesis is on HIV transmission and acquisition, the term “target cell” will be used to refer to 
CCR5+ CD4+ cells. 
Anatomy of the female genital tract 
The internal female reproductive organs can be divided into upper and lower portions 
(Figure 1.2A). The upper reproductive tract is comprised of the uterus, fallopian tubes, ovaries, 
and endocervix, of which all but the ovaries are lined by a columnar epithelium that is a single 
cell thick. The upper tract was traditionally thought to be sterile, but recent evidence calls this 
assumption into question (15, 16). The lower reproductive tract includes the entire vagina and 
spans from the vaginal introitus to the cervical os. The muscular vagina is lined by 20-30 cellular 
layers of stratified squamous epithelium that resembles skin (17, 18). But unlike the skin, the 
apical layers of the vaginal epithelium, called the stratum corneum, are not tightly adhered and 
rather form a loose, water-permeable barrier that is regularly sloughed (18). The stratum 
corneum also acts as a glycogen depot, providing a substrate for both epithelial cells and 
vaginal Lactobacillales bacteria to ferment lactic acid (17). The copious production of lactic acid 
maintains the vaginal pH at around 4 in women with Lactobacillus-dominant microbial 
communities (19). 
The superior end of the vagina is capped by the cervix, which contains a 2-3 cm canal 
leading to the uterus (20). The cervical canal is lined by goblet cells that produce mucus, a 
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viscous hydrocolloid that serves as a selectively permeable barrier and lubricant (21). Mucus is 
also an important component of the innate immune defense against both viruses and bacteria, 
partially due to its ability to bind the Fc domains of both IgG and IgA immunoglobulins (22). 
Thus, mucus protects the underlying epithelium, of which there are two types in the cervix: the 
stratified squamous epithelium of the ectocervix, and the columnar epithelium of the endocervix 
(Figure 1.2B,C). The transition between the ectocervix and endocervix is called the 
transformation zone, which contains a very high concentration of CD4+ T cells, CD8+ T cells, 
and macrophages (23) and is best known as a point of vulnerability in the epithelial barrier that 
is exploited by human papilloma virus and HIV.  
 
Figure 1.2 Anatomy of the female genital tract. (A) Schematic of the upper and lower female 
reproductive tract. (B) Magnification of the red box in (A), demonstrating the transition from the ecto to 
endocervix. (C) Histological magnification of the red box in (B), illustrating the position of the 
transformation zone (TZ) between the ectocervical stratified squamous epithelium and endocervical 
single layer of columnar epithelium. (B) and (C) adapted from Coombs et al. AIDS 2003 (24). 
Physiology of the female genital tract 
 The physiology of the female reproductive system is controlled by hormones, namely 
estrogen, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and 
gonadotropin-releasing hormone (GnRH). In a woman of reproductive age, GnRH is released by 
the hypothalamus and acts on the anterior pituitary, which subsequently releases FSH and LH; 
FSH and LH then stimulate the ovaries to produce estrogen and progesterone (Figure 1.3). 
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These hormones orchestrate the female menstrual cycle, which lasts an average of 28 days and 
is marked by two major events: the release of a single ovum by the ovaries and the preparation 
of the uterine endometrium for implantation by the fertilized ovum. If implantation does not 
occur, the endometrial lining is shed in menstruation. The first 4-5 days of the menstrual cycle 
are marked by menstruation. The period between the end of menstrual bleeding and ovulation is 
the follicular or proliferative phase. The last two weeks between ovulation and the initiation of 
menstrual bleeding is the luteal or secretory phase (Figure 1.3). 
 
Figure 1.3 Endocrine feedback control of female reproductive levels. (A) The hypothalamus releases 
gonadotropin releasing hormone (GnRH), which stimulates the anterior pituitary to make luteinizing 
hormone (LH) and follicle stimulating hormone (FSH). LH and FSH then stimulate the ovary to produce 
estradiol during the follicular phase and progesterone during the luteal phase. (B) Schematic of the 
female hormone levels throughout the menstrual cycle. Approximately the first four days of the cycle are 
the menstruation phase, followed by the follicular phase, which lasts up to ovulation. The second half of 
the cycle, after ovulation to the start of menstruation, is the luteal phase. Adapted from OpenStax 
College, 2013 (25). 
 
 LH and FSH are particularly important for the development and release of the ovum and 
are at their highest levels prior to ovulation (Figure 1.3B), while estrogen and progesterone 
affect the breasts, bones, adipocytes, and skin in addition to the female reproductive organs. 
There are three major forms of estrogen in the blood, with the most potent in non-pregnant 
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females being β-estradiol (26). Estradiol is low (below 100 pg/mL) in the first half of the follicular 
phase, peaks two days prior to ovulation, and remains at an intermediate concentration (around 
150 pg/mL) throughout most of the luteal phase. Alternatively, progesterone is only found at 
significant levels in the luteal phase (Figure 1.3B). Thus, measuring both estradiol and 
progesterone provide a rough estimate of where a woman is in her menstrual cycle. The 
pleiotropic effects of estrogen and progesterone on immune responses in the FGT are 
summarized in Table 1.1. 
 
Table 1.1 Effects of estrogen and progestins on aspects of the innate and adaptive immune 
response. Abbreviations include oral contraceptive pill (OCP), depo medroxyprogesterone (DMPA), 
cytotoxic T lymphocyte (CTL), and cervicovaginal (CV). 
 Estrogen Progestins 
Vaginal epithelial thickness Estrogen increases epithelial 
thickness in macaques (27) and 
humans (28) 
Progesterone decreases epithelial 
thickness in macaques (27) but 
DMPA does not affect thickness in 
humans (29) 
CCR5 expression on cervical 
CD4+ T cells 
Estradiol treatment of purified 
peripheral CD4+ T cells 
decreases HIV cellular entry 
without altering CCR5 
expression levels (30) 
OCPs increase CCR5 
expression on both cervical CD4+ 
and CD8+ T cells (31) 
Progesterone has been shown to 
both increase CCR5 expression 
on blood and cervical T cells (32), 
and decrease CCR5 expression 
on blood T cells (33)  
DMPA does not alter CCR5 
expression on vaginal mucosal 
CD3 cells (29)  
Cytotoxic T cell responses  Inhibition of CTL responses by 
DMPA (34) 
Lymphocyte migration Decreases T cell migration in 
vitro (35) 
 
Antibody production and 
transport 
Estradiol and progesterone decrease IgA, IgG, and secretory 
component in CV secretions of ovariectomized rats (36) 
 
Early events in HIV acquisition in the female genital tract 
Our understanding of the early events in HIV infection in the FGT are mostly derived 
from simian immunodeficiency virus (SIV) studies in non-human primate (NHP) models. 
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Following heterosexual intercourse with an infected partner, mucosal surfaces in the FGT are 
exposed to an enormously diverse quasispecies of genetically distinct cell-free virions and HIV-
infected seminal lymphocytes (37, 38) and yet a poorly understood bottleneck results in a single 
founder virus establishing the majority of new infections (39-41). SIV infection studies suggest 
that this single virion undergoes obligate local replication within the mucosal tissue for 1-7 days 
before disseminating to the draining lymph node and then the blood. Once virus has spread to 
the periphery, a widespread reservoir of latently infected cells is rapidly established and 
subsequent viral eradication becomes extremely challenging. This initial period of mucosal 
replication has been termed a “window of opportunity” for interventions that could contain virus 
locally and prevent systemic dissemination (42) (Figure 1.4).  
 NHP models indicate that following passage of virus across the cervicovaginal 
epithelium, the virion encounters susceptible CD4+ T cells targets and a small and highly focal 
founder population of 40-50 infected CD4+ T cells is established within 3-4 days of infection. 
The population of susceptible cells must be large enough to sustain a basic reproductive rate 
(R0) >1, such that one infected cell generates more than one newly infected cell, otherwise the 
infection will burn out (43). Simultaneously, the epithelial cells respond to viral exposure by 
secreting CCL20 (MIP-3α), which recruits plasmacytoid dendritic cells that subsequently secrete 
CCL4 (MIP-1β), IFN-α, and other chemokines (41). This sets up a delicate balance between 
interferon-induced protection and chemokine-driven recruitment of susceptible CD4+ T cells. 
Target cell recruitment by innate defenses likely overcomes the low density of target cells at 
baseline and facilitates cell-to-cell transmission to amplify the initial focus of infected cells (41) 
(Figure 1.4). 
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Figure 1.4 Model of the early events in HIV transmission and the important role of genital 
inflammation. The cervicovaginal epithelium is exposed to both cell-free and cell-associated HIV virions. 
Only a handful of virions are able to cross the epithelial layer, likely at the cervical transformation zone, 
endocervix or, if present, breaches in the thick vaginal epithelium. The virus replicates within the genital 
tissue for several days before being carried via the lymphatics to the draining lymph nodes, then 
eventually via the thoracic duct to the systemic circulation. Pre-existing genital inflammation increases the 
number of local CD4+ T cell targets and allows faster viral amplification. The innate immune response to 
viral exposure also recruits additional target cells, further stoking the inflammatory fire. Adapted from A.T. 
Haase, Nature, 2010 (41). 
 
The importance of inflammation in HIV acquisition and progression 
Given that effective viral replication and dissemination requires a sufficient density of 
target cells in the genital mucosa, elevated genital inflammation prior to HIV exposure may 
facilitate HIV acquisition by increasing the R0 through the recruitment of activated target cells 
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and the activation of resident CD4+ T cells that support greater HIV replication. In the absence 
of inflammation, healthy vaginal mucosa mostly contains resting CD4+ T cells, which do not 
support robust HIV replication, unlike activated T cells (44). Activated T cells are commonly 
identified by the markers CD38, a surface glycoprotein, and HLA-DR, an MHC class II molecule 
that is not expressed by resting T cells (45). It has been shown in vivo that human lymph node 
HLA-DR+ CD38+ CD4+ T cells have high cell surface concentrations of the HIV co-receptors 
CCR5 and CXCR4 and contribute to the majority of HIV-1 RNA production (median of 86%) 
occurring in lymph node CD4+ T cells (46). Specifically in the genital tract, the intracellular 
concentration of SIV RNA in activated (HLA-DR+) and proliferating (Ki67+) endocervical T cells 
was 4-7 times higher than in resting T cells (47). Thus, the frequency and activation state of 
CD4+ T cells in the FGT may have a critical role in determining the susceptibility to HIV 
acquisition. 
There are also several in vivo studies that support the importance of inflammation in HIV 
acquisition risk. In an SIV vaccine study with intrarectal challenges, macaques who became 
infected had twice as many CCR5+ HLA-DR+ CD4+ T cells in the rectum compared to those 
who remained uninfected, and there was a significant correlation between the pre-infection 
frequency of activated CCR5+ CD4+ T cells in the rectal mucosa and the day 7 plasma viral 
load (48). In serodiscordant couples, HIV acquisition was associated with elevated serum 
CXCL10 and IL-10 concentrations (49). In South African women enrolled in the CAPRISA 004 
study, plasma TNF-α and IL-12p70 and cervicovaginal IL-1α, IL-1β, TNF-α, CCL20 (MIP-1α), 
CCL4 (MIP-1β), and IL-8 were higher in women who acquired HIV (50, 51). The converse is 
also true; low systemic immune activation seems to have a protective effect in cohorts of highly 
exposed but seronegative hemophiliacs (52) and individuals in discordant couples (53).  
Inflammation continues to play an important role even after HIV transmission has 
occurred. In the genital tract, increased proinflammatory cytokine levels in cervicovaginal 
lavages (CVL) collected in early infection are also associated with a worse disease course, as 
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measured by higher viral load set points and CD4+ T cell depletion (54). In the blood, activation 
levels of CD4+ and CD8+  T cells were strongly correlated with decreased patient survival (55). 
In the gut, which harbors the vast majority of activated T cells in the body, CCR5+ CD4+ T cells 
are preferentially depleted within the first few weeks of infection (56). In fact, some studies 
suggest that the reduction in the number of Th17 cells in the gut leads to a decrease in the local 
IL-22 concentration, which causes the epithelial barrier to weaken. This leaky epithelium is 
thought to enable microbial translocation, thereby causing further systemic immune activation 
and increased target cell availability via TLR4 stimulation by translocated gut bacteria (57). 
Thus, both cellular and soluble inflammation affect HIV acquisition and progression. 
Social and behavioral risk factors for HIV acquisition in young women 
The risk of HIV transmission from an infected man to an uninfected woman is 
determined by the seminal viral load of the infected male, condom use, and the susceptibility of 
the female partner (7).  
The conventional “ABCs” of HIV prevention are “abstinence, be faithful, and use 
condoms”. Abstinence education is controversial and challenging from a policy perspective, but 
delaying sexual onset to an older age undoubtedly decreases a woman’s risk of HIV acquisition 
(58). Older women are more educated, financially independent, and assertive in negotiations 
with their sexual partners (59). 
Regarding “being faithful”, it is not unusual for men in sub-Saharan Africa to have 
multiple sexual partners; for example, up to 55% of men in Lesotho report having more than one 
regular partner or spouse (60). Multiple partners expand sexual networks and obviously 
increase the risk of HIV acquisition for everyone in the network. The tolerance of multiple 
partners is thought to come from cultural norms, the institutionalized authority of men over 
women in marriage, and more subtle control afforded to men from earning a higher income (61). 
Some women rely on their partners for financial support, creating a power dynamic that further 
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complicates negotiations for safe sex (62). It is also common in sub-Saharan Africa for younger 
women to have relationships with older men, 
who are more likely to have multiple partners 
and have HIV (59). This practice is thought to 
be the basis of the left shift in HIV prevalence 
curves for young women compared to young 
men (Figure 1.5) (1). 
The third component of the ABCs is 
using a condom. Male condoms are widely 
available and often free in clinics in sub-Saharan Africa, but adherence is controlled by the man. 
While female condoms are very effective, they are rarely used because they are harder to find 
and people are unfamiliar with how to use them (63). Stigma remains a general barrier to 
condom use, as demanding to use a condom may be perceived as a subtle confession of 
having HIV or another sexually transmitted infection (59). 
Biological risk factors for HIV acquisition in young women 
 There are numerous biological factors that are associated with an increased HIV 
acquisition risk in women. The most common biological risk factors are sexually transmitted 
infections, bacterial vaginosis, and injectable progestin-only hormonal contraceptives. 
Sexually transmitted infections 
The four sexually transmitted infections most robustly linked to HIV acquisition are 
herpes simplex virus 2 (HSV-2), gonorrhea, chlamydia, and Trichomonas vaginalis (64).  
Herpes simplex virus type 2 
Herpes simplex virus is a member of the herpes virus family and comes in two forms, 
called type 1 and type 2. HSV-1 primarily causes an oropharyngeal infection, while HSV-2 
 
Figure 1.5 Differences in HIV prevalence 
amongst young men and women. Adapted from 
Dellar et al., JIAIDS, 2015 (1). 
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infects the vulva and penis, although both types of HSV can infect both oral and genital sites. 
Both establish lifelong infection in the host, characterized by periods of latency in the sensory 
ganglion cells and recurrence in the skin innervated by the infected neurons (65). While the skin 
lesions can be very painful, most people who are seropositive for HSV-2 are asymptomatic (66). 
An active HSV-2 ulcer generates breaches in the epithelial barrier that are thought to 
facilitate HIV entry into the genital dermis and increase the risk of HIV infection by 2 to 4-fold 
(67). After HSV-2 lesions have healed, there remains an inflammatory focus that includes 
CCR5+ CD4+ T cells, which may contribute to increased acquisition rates even in the absence 
of lesions (68). Thus, both active and healed HSV-2 lesions impact HIV risk. 
Chlamydia trachomatis 
Chlamydia trachomatis is a gram-negative obligate intracellular bacterium that has a 
unique biphasic replicative cycle, existing as a tough, infectious elementary body (EB) when 
extracellular survival is required, and a fragile, non-infectious reticulate body (RB) when 
inhabiting an intracellular niche (69). The EB is able to enter the host epithelial cell, differentiate 
into a RB, replicate to form 100-1000 more RBs, and recondense those RBs back into EBs (69).  
About 48 hours after entering their host cell, newly produced elementary bodies can be released 
by either lysing their host or through exocytosis (69, 70).  
C. trachomatis poses a significant risk to women if untreated, due to its ability to cause 
pelvic inflammatory disease (PID) and eventually infertility by scarring the fallopian tubes (71). 
Chlamydia is easily treated with a short course of antibiotics, but women infrequently seek 
treatment due to the asymptomatic nature of most infections. However, clinical signs of local 
tissue damage and an inflammatory response are often present on exam, including a 
mucopurulent discharge from the cervical os and a friable cervical epithelium that bleeds easily 
(71).  
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Women with active C. trachomatis infections have elevated levels of numerous cytokines 
including IL-1β, IL-6, TNF-α, CXCL10 (IP-10), CCL20 (MIP-1α), CCL4 (MIP-1β), and RANTES 
in cervicovaginal lavages compared to women without any STIs or bacterial vaginosis (BV) after 
adjusting for coinfections and injectable hormonal contraceptive use (72). While CD4+ and 
CD8+  T cells are activated in response to chlamydia, both responses are short-lived and do not 
provide durable immunological memory, possibly because of direct bacterial inhibition (73). Due 
to this ineffective immune response, repeated untreated chlamydia infections result in chronic 
progressive inflammation, fibrosis, and scarring (69). 
Neisseria gonorrhoeae 
Like chlamydia, Neisseria gonorrhoeae is a gram-negative bacterium, over 50% of 
infected women are asymptomatic, and primary infection provides little protective immunity 
against repeated infection. Unlike C. trachomatis, N. gonorrhoeae is not an obligate intracellular 
bacterium, rather it uses its numerous pili and Opa proteins to adhere to nonciliated epithelial 
cells (74). After attachment, it triggers the host cell to phagocytose itself, and then manages to 
exit the cell through the basal surface (74). Within the mucosa, N. gonorrhoeae utilizes an 
arsenal of evasion mechanisms to inhibit complement activation, resist intracellular killing by 
phagocytes, and escape antibody recognition by antigenic variation (75). Given these 
sophisticated evasion mechanisms, perhaps it is no surprise that women with uncomplicated 
gonococcal infections do not have detectable increases in local pro-inflammatory cytokine levels 
or anti-gonococcal antibodies (72, 76, 77). 
Trichomonas vaginalis 
T. vaginalis (TV) is a protozoan flagellate that infects the vulva, vagina, and cervix in 
women and the prostate, seminal vesicles, and urethra in men. Infections are often 
asymptomatic but can cause a thin, white discharge accompanied by genital itching and burning 
(78). As a parasite, TV sometimes carries a virus called TVV (Trichomonas vaginalis virus) (79), 
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which amplifies the inflammatory reaction to TV (80). Without stratification based on TVV 
presence, TV is not significantly associated with any CVL cytokine changes, though there is a 
trend towards higher concentrations of IL-8 with TV (72, 81). 
Bacterial vaginosis 
Even in the absence of a frank STI, altered vaginal mictobiota in the context of bacterial 
vaginosis (BV) increases the risk of HIV acquisition by approximately 60% (82). Definitions for 
BV vary, but the clinically utilized Nugent score assesses the loss of the dominant gram-positive 
Lactobacillus species and presence of small and curved gram-variable rods that are often 
Gardnerella vaginalis, Mobiluncus, and Prevotella (Figure 1.6) (83). Over half of all women with 
BV are asymptomatic, but it is the most common cause for vaginal discharge. Using the Ansel 
clinical criteria of a vaginal pH above 4.5, increased watery vaginal discharge, presence of clue 
cells, and positive amine or whiff test, the estimated prevalence of BV in women of reproductive 
age in the United States is 29.2%, with significant variation among racial groups (with non-
Hispanic black women having the greatest prevalence of 51.4%) (84). Estimates for the 
prevalence in South Africa range from 15 to 70%  (82, 85).  
 
Figure 1.6 Examples of Gram stained vaginal smears with Nugent scores. Adapted from Nugent et 
al. Journal of Clinical Microbiology (83). 
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Hormonal contraceptives 
Injectable progestin-only contraceptives (IPCs) are a particularly popular contraceptive 
form in sub-Saharan Africa. IPCs have a minimal failure rate because they are extremely 
convenient to use, requiring a single injection once every two (for norethisterone enanthate, 
marketed as Nur-isterate) or three months (for depot-medroxyprogesterone/ DMPA, marketed 
as Depo-Provera). IPCs perform their contraceptive function by inhibiting the LH surge that 
triggers ovulation (Figure 1.7), increasing the thickness of cervical mucus to block the passage 
of sperm through the endocervical canal, and changing the endometrial lining to impair 
implantation (86, 87). They subsequently suppress the endogenous production of estradiol and 
progesterone (Figure 1.7).  
  
Hormonal contraceptives are a controversial risk factor for HIV acquisition. Many 
prospective studies in sub-Saharan Africa have sought to determine whether DMPA is 
associated with an increased HIV acquisition risk. The results are nearly evenly split (Table 
1.2), though a recent meta-analysis found a pooled hazard ratio of 1.4 and 95% CI of 1.16-1.69 
for DMPA use (88). There is less data available for Nur-isterate and oral contraceptive pills but 
the studies to date do not demonstrate an increased HIV risk compared to not using a family 
  
Figure 1.7 Suppressive effects of IPCs on endogenous estrogen, progesterone, and 
luteinizing hormone (LH) levels.  
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planning method (88). Several of these studies follow high-risk cohorts of sex workers (89, 90) 
and serodiscordant couples in stable relationships (91), but their unique sexual behaviors and 
underlying risk factors may hinder the general applicability of the study conclusions. Inclusion 
criteria also differ amongst studies, with the inclusion of older women between the ages of 35 to 
49 in several studies (92-94). Older women are more likely to use DMPA and be in a stable 
partnership, thus the effect size of DMPA might seem diminished due to less risky behavior. 
These confounders, which are inherent to observational studies, have led to the preparation of a 
highly controversial randomized control trial called the Evidence for Contraceptive Options and 
HIV Outcomes (ECHO) trial, which will randomize 7,800 women to use Depo-Provera, a 
hormonal implant called Janelle, or a copper intrauterine device. Critics of the proposed $48 
million trial do not believe that the study is ethical because it does not meet the criteria of clinical 
equipoise, meaning that there is genuine uncertainty about which treatment will be the most 
risky. Advocates consider the trial to be the only way to definitively answer the question of 
whether DMPA increases HIV risk.  
Table 1.2 Summary of prospective studies that tested the hypothesis that DMPA use was 
associated with an increased HIV acquisition risk. The hazard ratio (HR) and 95% 
confidence interval are shown for each study finding an increased risk. 
Demonstrated an increased HIV acquisition 
risk with DMPA use 
Found no difference in risk with 
DMPA use 
Crook et al. 2013.  HR 1.49 [1.06 - 2.08] (95) McCoy et al. 2013. (93) 
Heffron et al. 2012.  HR 1.98 [1.06 - 3.68] (91) Morrison et al. 2012. (96) 
Wand et al. 2012. HR 1.72 [1.19 - 2.49] (97) Reid et al. 2010. (94) 
Baeten et al. 2007.  HR 1.73 [1.28 - 2.34] (89) Myer et al. 2007. (92) 
Lavreys et al. 2004a. 
Martin et al. 1998a.     
HR 1.8   [1.4   - 2.4] (90) 
HR 2.0   [1.3   - 3.1] (98) 
Kiddugavu et al. 2003. (99) 
Kapiga et al. 1998. (100) 
 Bulterys et al. 1994. (101) 
aUtilized the same cohort. Lavreys extended the analysis to include the period of 1997-2003. 
 
 Unlike the clinical studies in humans, the non-human primate (NHP) model 
unequivocally demonstrates an increased risk of HIV acquisition with DMPA use (102-104). In 
fact, DMPA is routinely used to increase infection efficiency, synchronize hormone levels, halt 
menstruation, and thin the epithelial lining of vagina prior to intravaginal SIV and HIV infections 
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in NHP and humanized mouse models, respectively. The ability to extrapolate these finding to 
humans is hindered by differences in viral titer (very high titers are used in NHP challenge 
models to achieve high per-inoculation infection rates), the form of the virus (NHP are 
challenged with free virions in culture media, while women are infected by both cell-associated 
and cell-free virus in semen), and differences in the doses and physiologic responses to DMPA 
treatment (105).  
 The final complication is that medroxyprogesterone acetate (MPA) and norethisterone 
(NET), which is the metabolically-active hydrolyzed form of norethisterone enanthate, do not 
merely replace the biological effects of endogenous progesterone due to their differential effects 
on steroid hormone receptors (Table 1.3) (106). Progesterone, MPA, and NET all bind to the 
progesterone receptor but both IPCs have higher binding affinities than endogenous 
progesterone. Unlike progesterone, MPA and NET both bind to the androgen receptor, albeit 
very weakly (Table 1.3). Finally, the glucocorticoid receptor activity of MPA may be especially 
important due to the pleiotropic effects of glucocorticoids on nearly every organ system and 
lymphocytes (107, 108). 
Table 1.3. Relative binding affinities of progesterone, MPA, and NET to steroid 
hormone receptors. (+) indicates the magnitude of the effect, (±) indicates a weak effect, 
and (-) indicates a negligible effect. Adapted from (106). 
Progestin: 
Progesterone 
Receptor 
Estrogen 
Receptor 
Androgen 
Receptor 
Glucocorticoid 
Receptor 
Progesterone + - - + 
MPA +++ -	 ± +++ 
NET ++ - + - 
 
 In summary, the risk factors for HIV acquisition are a complex set of social, behavioral, 
and biological factors. The underlying mechanisms by which the numerous biological factors 
increase HIV susceptibility are uncertain, and this thesis focused on developing a better 
understanding of the inflammatory properties of cervicovaginal bacteria and injectable 
progestin-only contraceptives. 
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Introduction 
The female genital tract (FGT) maintains a finely-tuned immune response that balances 
reproductive tolerance with protection against genital infections. While inflammatory responses 
are beneficial and necessary for effectively eliminating several sexually transmitted infections 
(STIs), the presence of elevated genital inflammation in women prior to HIV exposure 
paradoxically increases the risk of disease acquisition (1, 2). Studies of the microbial causes of 
this inflammation have primarily focused on established pathogens such as Chlamydia 
trachomatis, Neisseria gonorrhoeae, HSV-2, and Trichomonas vaginalis. The potential role of 
commensal cervicovaginal bacteria, which number ~108 per gram of vaginal fluid (3), in 
modulating immune responses in the FGT is largely unknown. 
The bacterial microbiome of the healthy FGT has traditionally been thought to be 
exceedingly simple, predominated by a single Lactobacillus species in the majority of white 
premenopausal women (4-8). These species of Lactobacillus benefit the host by inhibiting the 
growth of pathogenic bacteria and fungi through the production of bacteriocins, lactic acid, and 
hydrogen peroxide (9, 10). Bacterial vaginosis (BV) is a symptomatic alteration of microbial 
communities in this ecological niche in which species of Lactobacillus are replaced by 
Gardnerella and Mobiluncus species. BV is associated with a 1.5–2-fold increased risk of 
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acquiring C. trachomatis, N. gonorrhoeae, T. vaginalis, and HIV (11, 12), which raises the 
question of whether specific genital microbial communities in asymptomatic women may more 
broadly modulate disease susceptibility.  
In addition to modulating disease acquisition risk, microbial changes have also been 
implicated in accelerating the progression of HIV to AIDS (13-15). Disease acceleration is 
thought to occur through two main pathways. The first is severe compromise of the gut mucosal 
epithelial barrier by HIV-mediated killing of protective CD4+ T cells, leading to impairment of 
barrier function, microbial translocation and chronic systemic inflammation (16-18). The second 
pathway is decreased microbial stability and shifts in the gut microbial composition towards 
more pro-inflammatory, pathogenic communities that add fuel to the inflammatory fire (13, 19-
21). The mechanisms leading to this gut microbial change in HIV infection are unknown, but the 
loss of effector CD4+ T cells leading to a failure to mount immune responses to pathogenic 
bacteria is one obvious possibility (22). Even less is known about changes in the vaginal 
microbiome in HIV infection, though studies published to date either failed to see a difference 
(23, 24) or saw less Lactobacillus crispatus in HIV-infected women (25). Longitudinal, high-
frequency bacterial characterization throughout the acute and chronic phase of HIV infection 
could provide more definitive evidence for HIV-induced microbial changes and provide important 
insight into the impact of host immune responses on microbial composition. 
To determine the contribution of cervicovaginal microbiota to genital inflammation, we 
evaluated a cohort of young South African women. Only a minority of HIV-negative study 
participants had Lactobacillus-dominant cervicovaginal communities, despite a lack of clinical 
symptoms, redefining what is considered to be normal in this region. We found a strong cross-
sectional and longitudinal in vivo relationship between high-diversity bacterial communities 
lacking Lactobacillus dominance and genital pro-inflammatory cytokine levels. We then 
compared the microbial community members of women who remained HIV-negative and those 
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who became infected. Finally, we determined the resilience of the cervicovaginal microbiome 
during the dramatic perturbation of acute HIV infection.  
Results 
A minority of South African women in FRESH had Lactobacillus dominant genital 
communities 
Participants were recruited through the Females Rising through Education, Support, and 
Health (FRESH) program, a prospective, 12-month observational study in Durban, South Africa. 
Participants had to be female, HIV-negative, nonpregnant, sexually active, and between the 
ages of 18 and 23 to be enrolled. Study volunteers attended classes twice a week that focused 
on empowerment, job skills training, and health education. Participants had a finger prick blood 
draw for HIV RNA testing at each visit, and completed a behavioral risk questionnaire and 
received a pelvic exam and venous blood draw every three months. Despite intensive 
counseling and STI testing, the HIV incidence in the cohort was 7%. If a participant acquired 
HIV during the study, she received further counseling, more frequent pelvic exams and blood 
draws, and was offered anti-retroviral therapy, as explained in more detail in the Methods 
section. 
We began by assessing the baseline bacterial microbiome in participants from the 
FRESH study. Following isolation of nucleic acid from cervical swabs, we sequenced variable 
region 4 (V4) of the bacterial 16S rRNA gene to assess bacterial abundances (26) (Figure  2.1). 
We chose to sequence the V4 region of the 16S rRNA gene due to the availability of extensively 
validated barcoded primers that are optimized for Illumina sequencing. While the V4 region has 
tremendous discriminatory power between most genera, it does not distinguish between all 
Lactobacillus species at a 97% operational taxonomic unit (OTU) level due to sequence 
similarity in that region.  
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We clustered the observed microbial communities into four distinct community types 
based on the dominant bacterial species, herein 
referred to as “cervicotypes” (CTs). While there has 
been some backlash against defining community 
types in the gut, our cervicotypes are primarily 
taxon-based classifiers as opposed to the cluster-
based classification of “enterotypes” (27), which 
renders cervicotypes more robust and biologically 
meaningful. CT1 was primarily composed of non-
 
Figure 2.2 Principal coordinates analysis 
using the weighted UniFrac distance 
metric on the same 94 samples, colored 
by cervicotype (CT). 
 
                 
Figure 2.1 16S analysis of cervical swabs reveals low Lactobacillus abundance and four 
distinct bacterial community structures. Heatmap of bacterial taxa identified by 16S V4 
sequencing of cervical swabs collected from 94 women. Cervicotypes (CTs) were determined based 
on the dominant species: Lactobacillus crispatus (CT1), L. iners (CT2), Gardnerella (CT3), and mixed 
microbial communities containing Prevotella (CT4). Nugent scores and alpha diversity are also shown. 
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iners Lactobacillus (i.e. higher percentage of sequencing reads from non-iners Lactobacillus 
than L. iners, Gardnerella, or Prevotella); CT2 was Lactobacillus iners dominant; CT3 had 
Gardnerella dominance; and CT4 lacked a consistent dominant species but communities all 
included Prevotella (Figure 2.1). Visualization of the same samples using a principal 
coordinates plot, which represents the phylogenetic distance between samples, supported the 
dominance-based clustering, though CT3 and CT4 are clearly a continuum (Figure 2.2). 
We found that only 37% of participants had Lactobacillus dominant cervicovaginal 
communities. This is in contrast to published reports of white and black women in developed 
countries in which 90% and 62% of women respectively demonstrated Lactobacillus dominance 
(4, 5). Of those women with Lactobacillus dominance in our study, 77% primarily had 
Lactobacillus iners (CT2). L. iners is biologically distinct from other Lactobacilli due to its unique 
adaptation to survive with diverse community members (28) and greater pathogenic potential 
(29, 30).  
Of the 63% of women in our cohort who did not have Lactobacillus dominance, 45% had 
Gardnerella dominant communities (CT3). The remaining 55% of women did not have a 
consistent predominant bacterial taxon, though each community was found to have at least 10% 
Prevotella abundance (CT4). Additionally, only half of the women in CT4 had BV, as measured 
by the Nugent criteria, which assesses a Gram-stained vaginal wet prep based on bacterial 
morphology; none of these women reported symptoms. Overall, the bacterial community 
structures seen in these asymptomatic young South African women are characterized by a 
predominance of communities with high ecological diversity and low abundance of non-iners 
Lactobacillus.  
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Figure 2.3 Summary of metagenomic taxonomic identification using whole-genome shotgun 
sequencing and oligotyping. (A) Heatmap of metagenomic taxonomic identification using the 
MetaPhlAn2 tool, with median clustering (dendrogram not shown). Six women with the highest pro-
inflammatory cytokine levels (red) and six with the lowest levels (black) were chosen for metagenomic 
profiling. Taxa with abundances greater than 0.01% in any sample were shown. Chlamydia trachomatis 
and Trichomonas vaginalis were only detected in women who were PCR positive (yellow box). Species 
tested in vitro are highlighted in green.  (B) Comparison of 16S (left) and whole-genome shotgun 
sequencing (WGS; right) taxonomic identification for all twelve participants for whom both methods were 
used. Note that MetaPhlAn2, the program that we used for bacterial classification of the WGS reads, does 
not include Sneathia or Shuttleworthia in its reference database (due to the absence of full genome 
sequences for these bacteria), and thus cannot assign those genera. Sneathia or Shuttleworthia reads 
from 16S sequencing are marked with an asterisk. (C) Oligotyping was performed on the reads that 
QIIME assigned to Lactobacillus (not iners) from women in CT1.  
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Figure 2.3 (Continued) 
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We next confirmed the 16S sequencing results and resolved specific community 
members at a species level by performing whole-genome shotgun (WGS) sequencing on 
cervical bacterial DNA from a subset of 12 women representing all four CTs (Figure 2.3A). Six 
women were among those with the highest pro-inflammatory levels, and six were among the 
lowest. WGS has proven useful for species-level taxonomic resolution when different bacterial 
species share nearly identical 16S rRNA variable regions (31, 32). The taxonomic classification 
by WGS had good agreement with 16S-based classification and STI PCR results (Figure 2.4 
and 2.3B). The additional species-level resolution provided by WGS also revealed that both of 
the women with CT1 analyzed by WGS had Lactobacillus crispatus dominant microbial 
communities (Figure 2.4A and 2.3C). We extended the analysis to every woman with CT1 
using taxonomic identification by oligotyping, a method which detects patterns in subtle 
nucleotide variations within the 16S gene (33), and found that nearly all women had identical 
sequences that aligned to L. crispatus, further validating that CT1 is mostly comprised of L. 
crispatus. 
 
 
Figure 2.4  Comparison of 16S (left) and whole-genome shotgun sequencing (WGS; 
right) taxonomic identification for all CTs. Participant #6 represents CT1 (A), #1 
represents CT2 (B), #7 represents CT3 (C), #11 represents CT4 (D). 
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Table 2.1 Contraceptive usage, active sexually transmitted infections, condom use, and sexual 
behavior are not associated with the bacterial community state. 
  All CT1 CT2 CT3 CT4   
 n=94 n=8 n=30 n=25 n=31  
STIs: n (%) n (%) n (%) n (%) n (%)   
Gonorrhea 1 (1%) 1 (12%) 0 (0%) 0 (0%) 0 (0%) p=0.08391 a 
Chlamydia 9 (9.6%) 0 (0%) 4 (13%) 2 (8%) 3 (9.7%) p=0.8855 a 
Trichomonas 6 (6.4%) 0 (0%) 1 (3%) 3 (12%) 2 (6.5%) p=0.5796 a 
HSV2 3 (3.1%) 0 (0%) 0 (0%) 1 (4%) 2 (6.5%) p=0.6197 a 
HSV1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) p=1.000 a 
No STIs 71 (75%) 7 (88%) 25 (83%) 19 (76%) 20 (64%) p=0.3609 b 
       
History of STIs (self-reported):            
Yes 18 (19%) 1 (12%) 10 (33%) 4 (16%) 3 (9.7%) p=0.09167 c 
No 72 (77%) 7 (88%) 18 (60%) 19 (76%) 28 (90%)  
Not available 4 (4.2%) 0 (0%) 2 (6%) 2 (8%) 0 (0%)  
       
Experiencing STI symptoms at time of exam: d            
Yes 2 (2.1%) 0 (0%) 1 (3.3%) 0 (0%) 1 (3.2%) p=1 c 
No 89 (95%) 8 (100%) 28 (93.3%) 24 (96%) 29 (93.5%)  
Not available 3 (3.1%) 0 (0%) 1 (3.3%) 1 (4%) 1 (3.2%)  
       
Contraceptive:            
No family planning 43 (46%) 4 (50%) 14 (47%) 10 (40%) 15 (48%) p=0.9474 c 
DMPA/ Nuristerate 42 (45%) 4 (50%) 14 (47%) 12 (48%) 12 (38%)  
OCP/ Non-hormonal contra. 9 (9.6%) 0 (0%) 2 (6%) 3 (12%) 4 (13%)  
       
Condoms in 30 days:            
Always 16 (17%) 3 (37%) 3 (10%) 4 (16%) 6 (19%) p=0.2775 c 
Sometimes 29 (31%) 4 (50%) 10 (33%) 7 (28%) 8 (25%)  
Never 27 (29%) 0 (0%) 12 (40%) 6 (24%) 9 (29%)  
No response/ no sex in past 30 days 20 (21%) 1 (13%) 3 (10%) 8 (32%) 8 (26%)  
       
# of sex episodes in past 7 days:            
None 47 (50%) 4 (50%) 10 (33%) 15 (60%) 18 (58%) p=0.2633 c 
One or more 43 (46%) 4 (50%) 17 (57%) 9 (36%) 13 (42%)  
Not available 4 (4%) 0 (0%) 3 (10%) 1 (4%) 0 (0%)  
       
# of regular sex partners in last 30 days:            
None 39 (41%) 3 (38%) 7 (23%) 15 (62%) 14 (45%) p=0.05377 c 
One 51 (54%) 4 (50%) 21 (70%) 9 (38%) 17 (555)  
More than one 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
Not available 4 (5%) 1 (12%) 2 (6.6%) 1 (4%) 0 (0%)  
       
# of casual sex partners in last 30 days:            
None 88 (94%) 7 (88%) 26 (93%) 24 (96%) 31 (100%) p=0.3131 c 
One 2 (21%) 0 (0%) 2 (6.6%) 0 (0%) 0 (0%)  
More than one 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
Not available 4 (5%) 1 (12%) 2 (6.6%) 1 (4%) 0 (0%)  
       
Days since last sexual act (Median, IQR): 8 [3, 26] 8 [6, 21] 6 [2, 19.75] 16.5 [4, 37] 14 [5, 52] p=0.275 e 
# of sex episodes in past 30 day (Median, IQR): 2 [0, 4] 2 [1, 4] 2 [1,4] 1.5 [0, 3] 1 [0,4] p=0.289 e 
# of anal sex acts in past 30 days (Median, IQR): 0 [0, 0] 0 [0, 0] 0 [0, 0] 0 [0, 0] 0 [0, 0] p=0.621 e 
Age of participant (Median, IQR) 21 [20,22] 21 [19.25, 22] 21 [20.75, 23] 21 [20, 22] 21 [20, 23] p=0.5631 e 
 
a. Fisher’s exact test, comparing each STI to those without that STI. 
b. Fisher’s exact test, comparing those with any STI to those without an STI. 
c. Fisher’s exact test, comparing all the groups lists under the subheading. 
d. Symptoms defined as itching, pain, burning, sores, foul smelling discharge, blood, and pain during sex. 
e. Kruskal-Wallis test, shown with median and interquartile range.  
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Cervicovaginal bacterial communities are not associated with sexually transmitted 
infections, hormonal contraceptive usage, or sexual behavior 
Women with BV have been shown to have a higher incidence and prevalence of STIs 
(12, 34), be less likely to use hormonal contraceptives (35), and be more likely to engage in 
high-risk sexual behavior (36). However, we did not find a difference in the prevalence of an 
active STI or STI symptoms between cervicotypes (Table 2.1), though the association with N. 
gonorrhea is difficult to ascertain due to its low prevalence in this group. Additionally, we saw no 
difference in hormonal contraceptive method, condom use, or reported sexual activity (Table 
2.1). Thus, there was no evidence that the high ecological diversity in CT4 was due to 
behavioral, infectious, or exogenous hormonal etiologies. 
Large variation in baseline genital immune activation is not explained by STIs 
Genital immune activation has been described as an important risk factor for disease of 
the FGT, such as obstetric complications (37, 38) and HIV acquisition (1, 2). We therefore 
assessed the cohort’s baseline genital immune activation by measuring the concentrations of 17 
soluble cytokines in cervicovaginal lavage (CVL) fluid from all participants who had completed at 
least one mucosal sampling. The cytokine panel included canonical pro-inflammatory cytokines 
(IL-1α, IL-1β, TNF-α), interferons (IFN-γ, IFN-α2), chemokines (CCL20 [MIP-1α], CCL4 
[MIP-1β], CCL5 [RANTES], CXCL10 [IP-10], CXCL8 [IL-8]), regulators of inflammation (IL-1 
receptor antagonist (IL-1RA), IL-10), differentiation markers (IL-4, IL-12p70), and activation and 
proliferation markers (soluble CD40L, FLT-3L, IL-2). There was a wide range in CVL pro-
inflammatory cytokine levels, with over a 1,000-fold difference in some cytokines ( e.g. IL-8 and 
IL-1α) among participants. We performed unsupervised clustering to visualize inflammatory 
patterns (Figure 2.5A) and found strong positive correlations (Spearman’s ρ > 0.4) between 
45% of cytokine pairs.  
To reduce the dimensionality of the cytokine dataset to a smaller number of covarying 
components, we performed principal component analysis (PCA) on the normalized cytokine 
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concentrations. We found that the first principal component (PC1) explained 41% of the 
variation in genital cytokines; PC1 represented the general presence of inflammatory cytokines, 
with high and nearly equal loading by all cytokines except for IL-1RA and CXCL10, which had a 
negligible contribution. Women in the highest or lowest quartile of PC1 had no difference in 
plasma cytokine levels, indicating that PC1 reflects local, not systemic, immune responses in 
the genital tract . 
 
We next asked whether women with the highest levels of cytokine inflammation had 
active STIs. Chlamydia trachomatis was the most prevalent active STI in this cohort, with 13% 
of women testing positive at the first visit. We found that women with C. trachomatis had higher 
inflammation than women without an STI (p=0.0226, Mann-Whitney test) but saw no trend with 
N. gonorrhoea, consistent with previous studies (39, 40). Of the 35 women in the top quartile of 
inflammation, 75% did not have a detectable active STI (Figure 2.5B). Women in the top 
 
Figure 2.5 Asymptomatic women display a broad range of baseline genital inflammation that is not 
explained by STIs. (A) Heatmap of cervicovaginal lavage cytokines from 146 women, each represented 
by a column. Nugent scores and active STIs (blue: C. trachomatis, N. gonorrhoea, T. vaginalis, and/or 
HSV-2 positive; gray: negative for that STI) are also displayed. Principal component (PC) analysis was 
performed on the normalized cytokine concentrations and the first PC (PC1) explained 41% of variation. 
(B) Pie chart of the STI prevalence in women in the highest quartile of inflammation (n=35). See also 
Figure S3 and Table S1.  
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quartile of inflammation also did not have higher rates of HSV-2 seropositivity (55% seropositive 
in both groups) or more unprotected vaginal recent sex, as determined by detectable prostate-
specific antigen in the CVL (2/15 in the high inflammation group, 1/19 in the low inflammation, 
p=0.5359) compared to women in the lowest quartile. Cytokine levels also did not correlate with 
sexual frequency, condom use, hormonal contraception use, or self-reported STI symptoms 
(Fisher’s exact test with p=0.05 significance level). Thus, the cause of elevated genital 
inflammation in the majority of women remained unexplained. 
High-diversity bacterial communities are strongly associated with pro-inflammatory 
genital cytokines 
To assess whether microbial communities might account for non-STI associated genital 
inflammation, we compared genital pro-inflammatory cytokine levels among CTs, with the 
hypothesis that Lactobacillus crispatus dominant CT1 would have the lowest inflammation due 
to the beneficial effects attributed to L. crispatus (9). To determine aggregate differences in 
cytokine concentrations, we first examined the value of cytokine PC1 in each CT. There was a 
highly significant difference across the cervicotypes (p<0.0001); between CT1 and CT4 
(p<0.01); CT2 and CT4 (p<0.001), and between CT3 and CT4 (p<0.05) (Kruskal-Wallis with 
post-test, Figure 2.6A), even after excluding women with any STIs.   
 To determine how strongly the presence of CT4, STIs, or BV associated with 
inflammation (defined by highest quartile of cytokine PC1), we calculated the odds ratios for 
each and found that only CT4 was significantly associated with cytokine PC1 (OR 4.33, 95% CI: 
1.575 –11.92; p=0.0046), though there was a trend for PCR-positive chlamydia (OR 2.380, 95% 
CI: 0.8497 – 6.666; p=0.1329) (Figure 2.6B). This indicates that women with CT4 are over four 
times more likely to have elevated genital pro-inflammatory cytokines than those with CT1-3, 
and that CT4 is a better predictor of inflammation than STIs or BV.  
 We next determined which of the cytokines that comprise PC1 were different between 
CTs. We observed significant increases in IL-1α, IL-1β, TNF-α, IFN-γ (p<0.0001, Figure 2.6C-
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F), IL-10 (p<0.01, Figure 2.6G), and CXCL8 (IL-8; p<0.05, Figure 2.6H), as well as IL-12p70, 
IL-4, and FLT-3L (p<0.01) in CT4 relative to CT1. Even after excluding women with any STIs, 
individuals with CT4 still had significantly higher levels of each of these cytokines relative to 
those with CT1. We observed a less pronounced increase in cytokines in CT3, with significantly 
higher IFN-γ than CT1, and a trend towards higher TNF-α, IL-8, and IL-10. The genital 
cervicotypes did not correlate with peripheral CD4+ or CD8+ T cell activation levels. Thus, the 
highly diverse bacterial communities in CT4 were strongly associated with the presence of 
multiple pro-inflammatory cytokines, suggesting specific genital bacteria can induce a robust 
local immune response. 
 
 
Figure 2.6 Genital pro-inflammatory cytokine levels vary significantly with microbial community 
structure and most strongly correlate with CT4 bacterial communities. (A) Cytokine PC1 values 
from women with bacterial communities CT1-4. (B) Odds ratios and 95% confidence intervals 
representing the likelihood that a woman with cervicotype 4, an active chlamydia infection, bacterial 
vaginosis (Nugent score >7), or an active Trichomonas infection is within the top quartile of pro-
inflammatory cytokine levels (as determined by cytokine PC1) versus below the 75th percentile. (C-H) 
Cervicovaginal lavage IL-1α, IL-1β, TNF-α, IFN-γ, IL-10, and CXCL8 (IL-8) concentrations in women with 
bacterial communities CT1-4. Median and IQR shown. Significance levels were determined by a Kruskal-
Wallis test and asterisks denote post-test significance level (* p < 0.05; ** p < 0.01; *** p < 0.001; n=94). 
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Longitudinal changes in genital microbial communities correlate with pro-inflammatory 
cytokines 
 Because of the close association between the genital bacterial communities and 
inflammation in cross-sectional analysis, we assessed the stability of these factors over time. 
We performed 16S rRNA gene sequencing and measured soluble cytokines on matched 
longitudinal cervical swabs and CVLs from all women who had been followed for 6-12 months at 
the time of analysis. In 58% of sequential time points, women remained in the same CT. Of 
those who had changes in microbial communities, there was a close association between CTs 
and IL-1α, IL-1β, and TNF-α, which we focused on because they had the strongest associations 
with CTs in the cross-sectional analysis. Data from two representative individuals who 
experienced CT changes are shown in Figure 2.7A. When we assessed sequential time points 
for which there was not a CT change, we did not find a significant difference in the canonical 
pro-inflammatory cytokines (p>0.05, one-tailed Wilcoxon matched pairs test; Figure 2.7B). 
However, there were significant increases in IL-1α (p=0.033), IL-1β (p=0.042), and TNF-α 
(p=0.030) in adjacent time points with transitions between a lower and higher CT (one-tailed 
Wilcoxon matched pairs test; Figure 2.7C). Thus, intra-individual changes in genital bacterial 
communities were tightly linked to inflammatory changes and further support the reciprocal 
relationship between bacterial communities and genital inflammation. 
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Figure 2.7 Intraindividual longitudinal genital microbiome changes correlate with pro-
inflammatory cytokine levels. (A) Cervicovaginal IL-1α, IL-1β, and TNF-α concentrations with 
bacterial taxa identified by 16S rRNA gene sequencing from matched longitudinal cervical swabs and 
CVLs collected from two representative participants, #13 and #14. (B-C) Cervicovaginal IL-1α, IL-1β, 
and TNF-α concentrations from serial time points with either no change in CT (B) or a change (C) 
(one-tailed Wilcoxon matched pairs test). The order of time points was standardized such that the 
lower cervicotype was entered as the first time point and the higher cervicotype was entered as the 
second time point, regardless of the actual chronological order. Any transition, e.g. from CT1 to CT2 
and from CT3 to CT4, was considered to be a CT change. 
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Women with elevated pro-inflammatory genital cytokines have increased activated 
cervical HIV target cells 
Given the close linkage between CT4 bacteria and genital inflammation, we sought to 
determine whether pro-inflammatory cytokines would correlate with the presence of activated 
HIV target cells in the genital tract. Activated CCR5+ CD4+ T cells at the cervical mucosal 
surface are likely the first susceptible cells 
to encounter HIV upon sex with an infected 
partner (41) and support greater HIV 
replication upon infection than resting cells 
(42). We found a significantly higher 
number of activated (CD38+ HLA-DR+) 
CCR5+ CD4+ T cells in the endocervical 
canal of women in the top quintile of 
cytokine PC1 relative to those in the 
bottom quintile (p=0.0361), but no 
significant difference in activated CCR5+ 
CD4+ T cells in the peripheral blood 
(Figure 2.8). Thus, the observed increase in genital HIV target cells supports the link between 
high diversity microbial communities and HIV acquisition risk. 
Trend towards increased HIV acquisition risk amongst women with CT4 bacterial 
communities 
 As both genital pro-inflammatory cytokines and BV have been associated with HIV 
acquisition risk in numerous studies, we hypothesized that women with CT4 bacterial 
communities have higher rates of HIV acquisition. At the time of analysis, fifteen women had 
acquired HIV in the FRESH study despite intensive education and counseling. Eight of those 
women had been enrolled in the study for long enough to have had a baseline pelvic exam prior 
 
Figure 2.8 Increased activated HIV target cells in 
the cervix but not the blood of women with 
elevated genital pro-inflammatory cytokines.  
Number of cervical and percentage of blood CD38+ 
HLADR+ CCR5+ CD4+ T cells from women in the 
highest and lowest quintile of cytokine PC1 (Mann-
Whitney, n=16 per group). 
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to HIV acquisition, and six had multiple pre-infection samples. The pre-infection cervical swabs 
most proximal to infection were collected between 25-149 days prior to HIV acquisition. 
Additionally, one participant coincidentally had a pelvic exam during the eclipse phase, just two 
days before HIV was detectable in her blood and the CVL viral load (VL) was close to the limit of 
detection with 400 copies/mL. The 15th participant to acquire HIV in the study was started on 
antiretroviral treatment (ART) just one week after becoming infected.  
We compared the pre-infection cervical bacterial communities of the women who 
acquired HIV to those who remained HIV-negative throughout the study duration. Two of the 
participants (Acute #8 and #11) had L. iners dominant communities, two (Acute #6 and 7) had 
Gardnerella dominance, and the remaining five had CT4 (Figure 2.9A). Several bacterial taxa 
were robustly enriched in women who became infected, including several Prevotella taxa, 
Sneathia, Peptoniphilus, and L. iners (FDR < 0.05, Mann-Whitney test), though their overall 
abundances were low. Determining HIV acquisition rate differences between CTs was 
hampered by low sample sizes; comparing the cervicotypes at the extremes, CT4 versus CT1, 
yielded a hazard ratio of 3.5 that did not reach significance, partially due to the generally low 
prevalence of CT1 in this cohort (Figure 2.9B). 
 
  
Figure 2.9 (A) Weighted UniFrac PCoA plot representing women who became HIV+ and those who 
remained HIV negative throughout the study. The most proximal HIV-negative sample collected prior 
to HIV infection was used. (B) Kaplan-Meier curve representing the HIV acquisition risks of women in 
CT1 versus CT4. The Hazard Ratio (Mantel-Haenszel) is 3.5, but it is not significant (p=0.245 using 
the Log-Rank test).  
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Viral dynamics in the genital tract 
 Following the first positive HIV PCR, plasma viral loads were measured from finger-
pricks twice a week for the first five weeks, once a week for the next four months, and once 
every three months after that. The first positive plasma viral load will herein be referred to as 
detection or day 0. CVL viral loads were measured at weeks 1, 2, 3, 5, 9, 12, 24, 36, and 48 
weeks post-infection, when available. The combination of early detection and high-frequency 
sampling post-infection affords the unprecedented opportunity to determine viral dynamics in 
the genital tract. All fifteen participants were found to be infected with HIV before peak viral load 
was reached in the blood (Figure 2.10A, B), with the peak plasma viral load occurring at a 
median time of 1.5 weeks after detection (Figure 2.10C). The participant who received very 
early ART had undetectable plasma and CVL viral loads by week 4.5. Interestingly, two 
participants (#8 and #11) consistently had CVL viral loads around the limit of detection despite 
not receiving ART. Both participants report only having vaginal sex, but not anal sex, within the 
past 30 days.  
Given the paradigm that HIV replicates locally in the genital tract for several days before 
disseminating systemically, we next asked whether the cervicovaginal lavage VL peaked prior to 
the plasma VL. We excluded three women for whom there was less than a 2 log difference 
between the nadir and peak VL, three woman for whom a week 2 CVL was not available and 
thus the peak VL could not be ascertained, and one woman who began ART at week 1. Despite 
including only 8 women in the analysis, the CVL viral load peak was significantly earlier  than in 
plasma by an average of 5 days (p=0.03, Figure 2.10C). While cervicovaginal VL significantly 
correlated with plasma viral load, the low R2 value indicates that the plasma VL provides some 
information about the cervicovaginal VL but the prediction is not precise (Figure 2.10D). This 
supports previous findings (43, 44) that the virus appearing in the CVL is not only a transudate 
from the plasma, but also reflects the distinct microenvironment of the local tissue. 
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Distinct bacterial and viral genital cytokine signatures 
 We next asked whether the inflammatory signature of HIV infection was distinct from the 
CT4 bacterial signature that we previously defined. We compared pre-infection CVL cytokine 
levels to those at peak CVL viral load in the eight women where paired samples were available. 
The virus-specific signature included CXCL10, CCL5, sCD40L, and GM-CSF, which all had 
significantly higher concentrations at peak genital viral load than before infection and were not 
associated with particular bacterial communities (Figure 2.11). IL-8 and TNF-α were common 
elements of the viral and bacterial signature, as they were higher in both HIV infection and CT4 
 
Figure 2.10 Very early of detection of HIV infection reveals divergent viral dynamics in the 
blood and genital tract. (A) Plasma and (B) cervicovaginal lavage viral loads measured over the first 
year of HIV infection. (C) Comparison of the time point where peak viral load is achieved in each 
compartment. There in an earlier viral load peak in the cervicovaginal lavage than plasma (Wilcoxon 
two-tailed test). The week of peak CVL viral load was only calculated in women for whom there was 2 
log difference between the nadir and peak, which excluded three participants (Acutes #5, #8, #11). 
Acute #1 and #3 was also excluded because a week 2 CVL was not available for viral load testing. (D) 
Correlation between plasma and CVL viral loads, with the Pearson r2 shown. 
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(Figure 2.11). Other components of the bacterial signature – IL-1α, IL-1β, IL-10, IFN-γ, and IL-
12p70 – were not significantly higher at peak viral load, and appear to be specifically associated 
with CT4. While we are unaware of other studies that measured CVL cytokine levels within the 
first two weeks of HIV-1 infection, the viral signature is consistent with a previous report in which 
CVL concentrations of CCL5, sCD40L, and TNF-α, but not GM-CSF or CXCL8, were found to 
correlate with HIV RNA level in CVLs collected six weeks postinfection (43). Thus, the bacterial 
and viral cytokine signatures in the genital tract are essentially distinct, reflecting differences in 
the host responses to these microbes.  
 
  
Figure 2.11 CXCL10, CCL5, CXCL8, sCD40L, GM-CSF, and TNF-α  are all found at 
significantly higher concentrations in the genital tract at peak CVL viral load 
(VL), compared to pre-infection levels. IL-1α (p=0.64), IL-1β (p=0.14), IFN-g 
(p=0.10), IL-10 (p=0.31), IL-12p70 (p=0.30) were not significantly different (data not 
shown.) P values were determined using a Wilcoxon matched-pairs signed rank test in 
8 women. The two participants with persistently low CVL viral loads are shown with 
dashed lines (Acute #8) and dotted lines (Acute #11); the timepoint of peak plasma VL 
was used in lieu of a lack of peak CVL VL. 
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Figure 2.12 16S rRNA gene sequencing analysis from high-frequency cervical sampling in the 
acute through chronic phases of HIV infection, and prior to infection when available. Day 0 is 
marked by the first positive HIV RNA results from a finger-prick test. Participants are roughly grouped 
in columns based on the most abundant cervicotype, with high CT1 abundance in the top left corner.  
N=15 
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Stability of the genital bacterial species and communities in acute HIV-1 infection 
 Finally, we extended the analysis to investigate the composition of cervicovaginal 
bacterial communities in acute through chronic infection. Given the significant CD4+ T cell 
depletion in both the genital tract and the peripheral blood that occurs in HIV infection (45), we 
hypothesized that the cervicovaginal microbiome would become destabilized in HIV infection, 
with a loss of bacteria that require CD4+ T cell interactions for survival, similar to B. fragilis in 
the gut mucosa (22). To address this question, we performed 16S sequencing on every 
available cervical swab using an identical procedure used for the HIV-negative swabs. The 
findings are summarized in Figure 2.12. 
Proteobacteria was the only bacterial phylum that 
was significantly different between the acute (first 
HIV+ swab available) and chronic timepoints and 
was much higher in the acute phase (p=0.001, 
Wilcoxon paired test with Bonferroni correction; 
Figure 2.13). The Proteobacteria phylum includes 
both Neisseria and, interestingly, Rickettsia. An 
unknown bacteria with 84% sequence identity with 
several Rickettsia species was found at persistently 
high levels (10-30% abundance) in Acute #4 from 
weeks 1 through 12 post-infection, and Acute #13 
also had up to a 13% abundance of the same bacteria between weeks 1-3. It was only found in 
one HIV-negative woman as a singleton. Validating and determining the significance of this 
likely Rickettsiales family member will require further investigation. No other individual species 
remained significantly different in acute versus chronic infection after multiple correction testing. 
Notably, Acute #15, who was the first participant to receive ARV therapy within the first week of 
infection, had a remarkably stable bacterial composition. Despite that observation, we have no 
   
Figure 2.13 Proteobacteria abundance 
in the acute phase of HIV infection 
versus the chronic phase.  
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reason to believe that HIV infection alters individual cervicovaginal bacterial members, though 
we may be missing a small effect due to small sample sizes. 
 Shifting the focus to communities rather than individual taxa, we compared the stability 
of the cervicotypes in the absence or presence of HIV. Since the HIV-uninfected women had 
pelvic exams every three month, but the HIV-positive women had more frequency sampling, in 
the analysis we only considered samples collected at approximately three month intervals. At 
these intervals, there was no difference in the likelihood of a participant remaining in the same 
CT (p=0.4830, Fisher’s test), arguing against a change in community stability (Figure 2.14). 
However we did find that an HIV-positive woman is less likely to have cervicotype 1 than an 
HIV-negative woman (p=0.0465, Fisher’s one-tailed test), confirming previous findings (25). 
Overall, the cervicovaginal communities remained fairly stable even when faced with an acute 
viral infection. 
 
Discussion 
In a cohort of young South African women, we defined four cervicovaginal bacterial 
community types and demonstrated a strong link between the high-diversity, Prevotella-
containing CT4 community type and genital inflammation in both cross-sectional and 
longitudinal analyses. Women with CT4 were over four times more likely to have high pro-
inflammatory genital cytokine levels than those with other CTs and on average had higher levels 
A  HIV negative  B  HIV positive 
  
To 
   
To 
 
  CT1 CT2 CT3 CT4 
  
  CT1 CT2 CT3 CT4 
From 
CT1 1 4 
 
  
 
From 
CT1   
  
  
CT2 2 7 1 2 
 
CT2   3 2 4 
CT3   1 1 3 
 
CT3   3 1 2 
CT4   1 3 15 
 
CT4   1 3 12 
 
Figure 2.14 Enumerating the cervicotype transitions at three-monthly intervals in 13 HIV-
negative women and 14 HIV-positive women (excluding Acute #15 who received early ART.) 
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of genital inflammation than women with BV or STIs. Women who were infected with HIV while 
enrolled in the study had an enrichment of particular Prevotella, L. iners, Sneathia, and 
Peptoniphilus taxa prior to infection, and there was a trend towards women with CT4 having 
higher infection rates than those with L. crispatus dominant CT1. Finally, the cervicovaginal 
microbial communities are surprisingly resilient to the perturbation of HIV infection, and do not 
display a consistent change after infection. Overall, these findings suggest that cervicovaginal 
bacteria are a major contributor to the basal inflammatory state of the female genital tract and 
influence HIV acquisition risk. 
High prevalence of bacterial communities with low Lactobacillus abundance 
Only 37% of participants had CT1 or CT2 bacterial communities, clearly indicating that 
Lactobacillus dominance is not typical in this population. This is in contrast to studies in the 
U.S., in which 90% of white women were found to have Lactobacillus dominance (4), but 
consistent with previous studies that used Gram stain analyses to demonstrate a high 
prevalence of BV in sub-Saharan African women (46, 47). We report a common occurrence of 
low Lactobacillus, high-diversity communities even in the absence of BV and provide a 
comprehensive characterization of bacterial taxa using high-throughput sequencing. 
The etiology of the low Lactobacillus abundance in our cohort remains unexplained. It 
was not associated with sexual behavior, contraceptive usage or demographic characteristics 
and we speculate that host genetic factors may play a role. Previous studies have demonstrated 
a lower frequency of L. crispatus and L. jensenii and a higher frequency of Prevotella in black 
and Hispanic women compared to white and Asian women in the U.S. (4, 5). The high diversity 
vaginal communities seen in black American women showed general similarities to those seen 
in black South African women, specifically with high levels of Prevotella, but the prevalence of 
these high-diversity communities was approximately half of that observed in South Africans. 
Studies of African cohorts have also demonstrated a higher intestinal Prevotella abundance 
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than in American and European cohorts (48, 49) suggesting that vaginal seeding from the 
bacteria-rich rectum (50) may also influence the observed differences. Overall, our findings 
support the growing understanding that Lactobacillus dominance is not tantamount to a 
“healthy” female genital tract microbiome in all women (4), and they highlight the value of 
bacterial characterization in broader geographic regions. 
Strong associations between cervicotypes and cytokines 
 We found that CT4, and CT3 to a lesser extent, are strongly associated with IL-1α, IL-
1β, TNF-α, IL-10, IFN-γ, IL-12p70, and CXCL8 (IL-8) concentrations in the CVL, while HIV 
infection leads to the upregulation of CXCL10, CCL5, sCD40L, GM-CSF, CXCL8, and TNF-α. 
IL-1β has consistently been associated with BV, regardless of sample collection method, 
pregnancy status, and BV diagnosis method (Nugent vs. Amsel criteria). However, differences 
in TNF-α, IL-10, and IL-8 have been infrequently and inconsistently reported, and IFN-γ and IL-
12p70, to our knowledge, were never found to be associated with BV (51-57). Our results 
elucidate this discrepancy. The traditional Nugent score is calculated by enumerating the 
number of lactobacilli morphotypes, Gardnerella or bacteroides morphotypes, and curved Gram-
variable rods (usually Mobiluncus) observed on a Gram stain (58). Nearly all studies to date 
have compared women with BV (either a high or intermediate score) to those without BV. 
However, we found that the women with highest levels of pro-inflammatory cytokines harbor a 
particular community type that is Prevotella-rich, and Gardnerella and Lactobacillus-poor. 
Additionally, the BV score is agnostic to the type of Lactobacillus species present, and we saw a 
clear trend towards lower levels of IL-1α, IL-1β, and IFN-γ in women with L. crispatus versus L. 
iners in both cross-sectional and longitudinal analyses, a finding that has very recently been 
demonstrated in a different cohort (59). Thus, the Nugent criteria are too coarse to capture 
subtle variation in the vaginal microbiota, and molecular characterization of bacterial 
communities provides greater insight into host-bacterial interactions.  
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Distinct cytokine patterns associated with bacterial communities and viral infections 
The in vivo bacterial and viral genital cytokine signatures that were found had a striking 
resemblance to previously reported in vitro studies in which dendritic cells were exposed to 
Gram-negative bacterial components or viruses (60, 61). For example, one study treated 
dendritic cells with either E. coli or influenza and found that the genes preferentially upregulated 
in response to influenza infection included those encoding for CXCL10 (strongly), CCL5, and G-
CSF, while those upregulated after E. coli treatment included IL-1α, IL-1β (strongly), IL-12p70, 
IL-10, and CXCL8  (60). IFN-γ and sCD40L were not among the differentially regulated dendritic 
cell genes and are likely of T cell origin. The origin and significance of the bacterial cytokine 
signature is explored further in Chapter 3 of this thesis.  
Relative stability of L. iners-dominant and CT4-dominant communities in both HIV-
negative and HIV-positive women and its implications 
 While the majority of studies utilize a cross-sectional study design, the vaginal 
microbiome is increasingly appreciated to be dynamic. Longitudinal studies employing daily (62) 
or twice-weekly (63) self-collected vaginal swabs in healthy American women found that the 
most stable community types were those dominated by a single Lactobacillus species or the 
poorly defined community state type IV-A (4). Our analysis was limited by a small cohort and 3-
month sampling intervals in the HIV-negative phase. However, the most stable state in both 
HIV-negative and HIV-positive women appeared to be CT4, with about a 75% likelihood of 
remaining in CT4 in a 3-month interval. L. iners-dominant CT2 was the second most stable 
community. The overall stability of the cervical microbiome also did not appear to change with 
HIV infection, as the uninfected women remained in the same CT between serial samples 58% 
of the time, and the HIV infected women did so 52% of the time. Unfortunately our study did not 
have the power to determine factors that stabilize or destabilize the microbiome, but prior 
studies found that the lowest stability was associated with menses (63). The vast majority of 
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women (>95%) in our study underwent mucosal sampling outside of their menses, thus it is very 
unlikely to account for the fluctuations that we saw. 
 The issue of microbial stability becomes particularly important when determining the 
relationship between the vaginal microbiome and HIV acquisition risk. Reducing the time 
between the HIV acquisition event and the adjacent previous visit where the genital sampling 
was performed is critical to drawing accurate conclusions. In large studies, vaginal sampling at 
intervals less than one month is logistically difficult for both study coordinators and participants. 
Thus, having the ability to use an archived sample to confidently predict what the vaginal 
microbial composition was at the time of acquisition would be enormously helpful. Alternatively, 
if HIV does not effect the vaginal microbiome, studies like ours utilizing high-frequency HIV 
testing could use the first HIV+ sample as a proxy for the microbial composition at the time of 
acquisition. Our study suggests, but does not show definitively, that HIV does not significantly 
alter the vaginal microbiome in very early acute infection. For example, consider Acute #7, who 
was coincidentally sampled in the eclipse period where her CVL viral load was close to the limit 
of detection and plasma viral load was negative. She had essentially the same microbial 
composition two days later, when her plasma viral load had reached a detectable level at 390 
copies/mL. Overall, the relative stability of CT4 at a three-month interval is encouraging for 
previous studies that investigated the relationship between BV and HIV acquisition risk using a 
similar sampling interval (64, 65).  
 
Impact of cervicovaginal microbiota on HIV acquisition risk 
 Numerous studies have now shown the two-fold increased risk of HIV-acquisition 
amongst women with BV (reviewed in (11)), but all of these studies have relied on the Gram 
stain for bacterial characterization. While our study is not powered to determine the HIV 
acquisition risk amongst women with CT4 communities, we did see differences in the pre-
infection samples of women who became infected compared to those who remained HIV-
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negative. Women who became infected had significant enrichment in several CT4 bacteria: 
Prevotella, Sneathia, and Peptoniphilus. The pro-inflammatory properties of Prevotella and 
Sneathia are examined in greater detail in Chapter 3, but larger studies, in vitro models, or novel 
animal models will be required to determine whether these bacteria directly increase HIV 
acquisition risk.  
Materials and Methods 
Study cohort and schedule 
Participants were recruited through the Females Rising through Education, Support, and 
Health (FRESH) study, a prospective, 12-month observational study of women 18-23 years old 
conducted outside of Durban, South Africa. At the time of data analysis, 146 participants had 
completed at least one mucosal sampling. The study protocol was approved by the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal (Durban, South Africa) and the 
Massachusetts General Hospital Institutional Review Board (2012P001812/MGH; Boston, MA). 
Informed consent was obtained after the nature and possible consequences of the study were 
explained. To be eligible for the study, participants had to be female, 18-23 years old, HIV-
negative, able to understand the information and consent forms, willing to adhere to study 
requirements, willing to have HIV testing performed twice-weekly, and willing to have samples 
stored. Participants could not be pregnant, anemic, or enrolled in any other study. 
Twice-weekly volunteers had a finger prick blood draw for HIV RNA testing and every 
three months had a pelvic exam, peripheral blood draw, and completed an HIV risk 
questionnaire administered by a counselor. 
If a participant was found to be HIV+ by finger-prick, the test was repeated and 
confirmed the next day. The participant then arranged to have a pelvic exam within the next four 
days (“week 1”) and at weeks 2, 3, 5, 9, 12, 24, 36, and 48 thereafter. Finger-prick HIV RNA 
testing was performed at weeks 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 12, 24, 36, and 48. 
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After the protocol amendment was approved, all  participants were offered anti-retroviral 
treatment within the first week of infection detection; unfortunately the approval did not occur 
until the 15th participant became HIV+.  
Sample selection 
 At the time of analysis, samples were available from 146 study participants who had 
completed at least one mucosal sampling, 13 participants who had completed at least three 
samplings, and 15 participants who acquired HIV. Of these 146 participants, we performed 16S 
sequencing on all subjects who had a complete set of cervical swab, CVL, and cellular 
phenotyping data (n=94). 
Sample collection 
The mucosal sample collection involved the collection of ectocervical and midvaginal 
swabs (Catch-All, Epicentre), a cervicovaginal lavage, and an endocervical cytobrush. 
A single nurse performed all the pelvic exams. Ectocervical and midvaginal swabs were 
immediately placed into sterile cryovials after collection and stored at 4°C for 1-3 hours during 
transport to the laboratory, followed by long-term storage at -80°C. The first posterior fornix 
swab was sent to Global Labs (Durban, South Africa) for sexually transmitted infection testing. 
At the first and fourth pelvic exam visits, the second posterior fornix swab was rolled onto a 
glass slide, allowed to air dry, and a Gram stain and Nugent scoring (58) were performed by 
Global Labs.  
The cervicovaginal lavage was performed by washing the cervicovaginal walls with 5 mL 
of sterile saline using a sterile Pasteur pipette. The lavage was kept at 4°C for 1-3 hours during 
transport to the laboratory, where it was centrifuged at 1700 rpm at 4°C to fractionate the 
cellular component from the supernatant. The supernatant was aliquoted and stored at -80°C, 
and subsequently used for cytokine measurements. 
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Cellular collection was performed by fully inserting a cytobrush (Cytobrush Plus GT, 
Cooper Surgical) into the endocervical canal and rotating twice exactly 360°. Immediately after 
collection, the cytobrush was placed into antibiotic supplemented RPMI media with 10% FCS 
and stored at 4°C for 1-3 hours. In the laboratory, the cells were dislodged from the cytobrush 
and washed prior to cell surface staining and FACS analysis.  
Peripheral blood mononuclear cells were isolated from blood using a standard Ficoll 
gradient. 
BV, sexually transmitted infection (STI), and PSA detection 
Vaginal smear Gram staining, Nugent scoring for BV, and STI testing were performed by 
Global Labs (Durban, South Africa). Neisseria gonorrhoea and Chlamydia trachomatis were 
tested using the GeneXpert CT/NG assay (Cepheid). Trichomonas vaginalis, HSV-1, and HSV-
2 were tested by real-time PCR on a LightCycler (Roche). All positive results for Trichomonas, 
HSV-1, and HSV-2 were retested, and inconsistent results were sent to an outside lab for a third 
confirmatory test. HSV-2 seropositivity was determined by the HerpeSelect 2 ELISA IgG kit 
(Focus Diagnostics) on 36 plasma samples. Prostate-specific antigen concentrations were 
tested using the PSA Quantikine ELISA (R&D Systems) on undiluted cervicovaginal lavage 
samples. Genital HSV-1 results were negative in all women whose samples were used in this 
study and thus are not referred to in the manuscript. Women with positive STI results were 
referred for treatment at an outside facility 
Nucleic acid extraction from cervical swabs 
We chose to utilize ectocervical swabs for microbial profiling, though we also had vaginal 
swabs available, because of the closer proximity of the ectocervix to the endocervical canal 
where the cellular sampling was occurring. The ectocervix is also more relevant to HIV 
transmission, which is thought to be more likely to occur through the cervical epithelium than the 
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multi-layered vaginal epithelium (41). Regardless, cervical and vaginal microbial populations are 
very similar based on data from other studies (66) and our cohort (data not shown).  
Swabs were thawed on ice, placed into a solution of phenol:chloroform:isoamyl alcohol 
(25:24:1, pH 7.9, Ambion), 20% sodium dodecyl sulfate (Fisher), Tris-EDTA buffer, and 0.1mm 
glass beads (BioSpec), and then vigorously rubbed against the walls of the tube. The solution 
was homogenized using a bead beater for 2 minutes. Following centrifugation at 6,000xg for 3 
minutes, the aqueous phase was transferred to a clean tube and an equal volume of 
phenol:chloroform:isoamyl alcohol was added and mixed by vortexing. Following a second 
centrifugation at 14,000xg for 5 minutes, the aqueous phase was transferred to a clean tube. 
Nucleic acid was precipitated with isopropanol and 3M sodium acetate pH 5.5 (Ambion) 
at -20°C overnight and then centrifuged at maximum speed for 30 minutes at 4°C. The 
supernatant was discarded and the pellet was washed by adding 0.5mL of 100% ethanol, 
centrifuging for 15 minutes at 4°C, and discarding the supernatant. The nucleic acid pellet was 
allowed to dry and was resuspended in 20 µL of molecular grade Tris-EDTA buffer (Promega). 
The nucleic acid concentration was measured using a Nanodrop (Thermo Scientific). 
PCR amplification and sequencing of the V4 region of bacterial 16S rRNA gene 
Each cervical nucleic acid sample was diluted to 100 ng/µL using ultra-pure water 
(MoBio) prior to PCR amplification. PCR amplification was performed using the Phusion High-
fidelity polymerase (New England Biolabs) in triplicate, with each well containing 2 µL template 
DNA. A no-template control was performed for each barcode pair on the same plate. PCR 
reactions were performed with the following settings: denaturation for 30 s at 98°C, 30 cycles of 
98°C for 10 s, 57°C for 30 s, and 72°C for 12 s, with a final extension for 10 m at 72°C. 
Triplicate PCR reactions for each sample were then combined into a single volume. Amplicons 
for each sample and a no-template control with the same barcode pair were run on a 1.5% 
agarose gel to confirm the presence of a single band at roughly 300-350 bp in the amplicon and 
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absence of a band in the no-template control. Amplicons were quantified by Picogreen 
(Invitrogen) and equal amounts from each sample were pooled. The amplicon pool was cleaned 
using an UltraClean PCR Clean-up Kit (MoBio). The library was sequenced with a single 1x300 
bp run on an Illumina MiSeq at the Center for Genome Sciences at Washington University in St. 
Louis using a 10% PhiX spike-in and custom sequencing primers, as described previously (67). 
16S sequence quality control and taxonomic classification 
Of the 13,964,311 input sequences, 5,975,498 reads passed the quality filtering step 
(minimum quality score of 30) and were assigned to samples using split_libraries.py. 
Operational taxonomic units (OTUs) were assigned using open-reference picking (97% identity, 
Greengenes v.13.8) with default parameters except for 0.1% subsampling. The median 
sequence count/sample was 40,657 with a standard deviation of 14,318. With a rarefaction cut-
off of 10,000, one sample containing 1,521 counts was excluded from further analysis. Taxa 
with fewer than 5 reads were filtered, and the remaining taxa were summarized at the species 
level. 
The principal coordinates plot was generated in EMPeror using the weighted UniFrac 
(68, 69) method with rarefaction of 2,000 reads per sample. Alpha diversity was calculated 
using Faith’s phylogenetic diversity using the PD_whole_tree QIIME command. 
Cervicotype determination 
“Cervicotypes” were defined as follows: CT1 has a higher percentage of reads assigned 
by QIIME open-reference OTU picking to the genera Lactobacillus (but not L. iners) than L. 
iners, Gardnerella, or Prevotella; CT2 has a higher percentage of reads from L. iners than 
Lactobacillus, Gardnerella, or Prevotella; CT3 has a higher percentage of reads from 
Gardnerella than Lactobacillus, L. iners, or Prevotella; and CT4 is the remaining samples that 
lack dominance in Lactobacillus, L. iners, and Gardnerella. Shotgun DNA sequencing and 
oligotyping analyses demonstrated that CT1 was mostly composed of Lactobacillus crispatus. 
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Metagenomic shotgun DNA sequencing and taxonomic classification 
Shotgun DNA libraries were made from total nucleic acid isolated from 12 cervical swab 
samples; the same total nucleic acid was used for 16S amplification. The samples were chosen 
based on CVL cytokine levels (six with very high inflammation, six with very low inflammation). 
DNA was isolated from total nucleic acid using an AllPrep DNA/RNA Micro Kit (Qiagen). 
Methylated DNA was removed using a Microbiome DNA Enrichment kit (New England Biolabs) 
to enrich for microbial DNA. Microbial DNA was sheared using an S2 sonicator (Covaris) and 
DNA was sized and quantified using a high-sensitivity DNA Bioanalyzer chip (Agilent). DNA 
libraries were prepared using a NEBNext DNA Library Construction kit (New England Biolabs), 
following manufacturer’s directions with the double-sided SPRI bead cleanup option. The final 
library was sequenced on a paired-end 250 bp Illumina MiSeq run. The final library had a 
median size of 480 bp and was sequenced on a paired-end 250 bp run using the Illumina MiSeq 
at the Center for Genome Sciences at Washington University in St. Louis. After demultiplexing, 
each sample had 703,954 - 1,148,817 reads. Quality control filtering and adapter trimming were 
performed using fastq-mcf (70), with a quality threshold of 25, 0.01% “N” percentage causing 
cycle removal, and minimum remaining sequence length of 25. The forward and reverse reads 
of each sample were concatenated prior to MetaPhlAn2 analysis. 
Using MetaPhlAn2, we detected the same genera using 16S and WGS methods for 
every bacteria with an abundance over 1%, with the exception of Sneathia and Shuttleworthia, 
which are under-represented in the available marker database due to a paucity of full-genome 
reference sequences. 
Bacterial functional pathways analysis 
Reads aligning to the human genome or PhiX were removed from quality controlled and 
adapter trimmed shotgun DNA sequences. The remaining reads were assigned to KEGG genes 
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using a translated BLAST search, and HUMAnN (was used to identify the differentially abundant 
microbial pathways (71). 
Oligotyping 
 Oligotyping analysis (33) was performed on 16S V4 sequencing reads that were 
assigned by QIIME to the Lactobacillus genera but not to a specific species. A total of 233,821 
sequences were analyzed; all had Phred quality scores above 30 and were trimmed to 270 
bases. Seven base locations of interest (57, 59, 115, 124, 155, 214, and 245) were used to 
determine oligotypes. The resulting oligotypes had maximum Shannon entropy scores less than 
0.2, which is within sequencing noise, indicating that the majority of subtle nucleotide variation 
was captured. Representative oligotypes were searched in the nucleotide BLAST database; the 
two most abundant oligotype sequences were: 
>Oligotype GCTGCAC 
TACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGAAGAA
TAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAACTGCATCGGAAACTGTTTTTCTTG
AGTGCAGAAGAGGAGAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAG
AACACCAGTGGCGAAGGCGGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATG
GGTAGCGAACAGGATTAGAAACCCTAGTAG 
>Oligotype GCTGCAT 
TACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGAAGAA
TAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAACTGCATCGGAAACTGTTTTTCTTG
AGTGCAGAAGAGGAGAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAG
AACACCAGTGGCGAAGGCGGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATG
GGTAGTGAACAGGATTAGAAACCCTAGTAG 
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Determination of bacterial taxa enriched in women became HIV+ 
 All HIV-negative and HIV-positive 16S rRNA gene amplicon sequences that were 
trimmed to a quality score of 30 were combined and open-reference OTU picking with 97% was 
performed at the 97% OTU level. The OTU table was filtered to remove OTUs with less than 
100 reads and OTUs that were not present in at least 10% of samples, then rarefied to 10,000 
reads per sample. The group_significance.py function was then used to compare the samples 
from women who remained HIV-negative to the pre-infection samples most proximal to the time 
of infection using a Mann Whitney U test. 
Cytokine measurements in CVLs 
Cytokines were measured using a human cytokine/chemokine multiplexed bead assay 
(Millipore). Cervicovaginal lavages (CVL) were analyzed within six months of collection and 
underwent a single freeze-thaw cycle. CVLs were thawed on ice, centrifuged for 10 min at 
1,000xg and 4°C, and the undiluted supernatant was immediately assayed. GM-CSF, IL-1β, IL-
2, IL-4, IL-6, CXCL8, CXCL10, IL-12p70, IFN-γ, and TNF-α were measured with a high-
sensitivity kit. G-CSF, IL-1α, IL-1RA, CXCL10, CCL3, CCL4, CCL5, sCD40L, FTL-3L, and IFN-
α2 were measured with a regular sensitivity kit. The multiplexed bead assay was performed 
according to the manufacturer’s protocol. A quality control was included with every plate to 
ensure reproducibility. Cytokine measurements below the limit of detection were assigned to a 
value of half of the minimum detectable concentration for that cytokine. When generating the 
heatmap and correlation matrix, measurements for each cytokine were first normalized by 
taking the log10 of the cytokine concentration, subtracting the mean measurement for that 
cytokine, and dividing by the standard deviation. The cytokine heatmap was generated using 
the complete clustering method on the Euclidean distance matrix. 
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Statistics 
Mann-Whitney Wilcoxon test was used to compare continuous data between two 
groups. For comparisons between more than two groups, Kruskal-Wallis test with post hoc 
analyses was used. Wilcoxon signed rank was used to compare continuous data between two 
time-points. Fisher’s exact test was used for comparing categorical data among two or more 
groups. Spearman’s correlation coefficients were used to examine associations between 
variables; only correlations with a P value lower than the specified cut-off are displayed. 
Principal component and cluster analyses were used to obtain summary measures for 
cytokine/bacteria variables and to identify study subjects with similar cytokine/bacteria profiles. 
Multivariate analyses using ridge regression (72) were used to identify the correlates of higher 
cytokine values. P-values are two-sided and are not adjusted for multiple testing. The analyses 
were performed using R Studio and Prism (GraphPad). 
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Introduction 
 The striking cross-sectional and longitudinal association between cervicovaginal pro-
inflammatory cytokines and high-diversity, Lactobacillus-deficient bacterial communities 
provokes the question of how these bacteria are sensed by genital innate immune cells. There 
is a surprising dearth of mechanistic understanding of host–symbiont bacterial interactions in 
the genital tract, but the gastrointestinal tract and skin serve as valuable paradigms. Symbiotic 
gut and skin bacteria play critical roles in maintaining local tissue homeostasis through 
interactions with epithelial cells, macrophages, dendritic cells, Tregs, and Th17 cells (reviewed 
in (1) and (2)). Toll-like and NOD-like receptors are among several innate sensors used by 
epithelial cells and antigen presenting cells (APCs) to sense and respond to bacteria at these 
sites (3-5). The pathways by which particular cervicovaginal bacterial communities elicit pro-
inflammatory cytokine production from local APCs and epithelial cells is poorly understood. 
 Dendritic cells and macrophages are the primary APCs of the cervix and vagina, and 
they function by directing T cell responses, initiating and resolving inflammation, and 
maintaining tissue homeostasis  (6, 7). The most prevalent APC in the stratified squamous 
epithelia of the vagina, ectocervix, and ectocervical side of the transformation zone are 
Langerhans cells that express HLA-DR, CD11c, and Langerin or CD1a (8, 9). Langerhans cells 
are not present in the columnar epithelium of the endocervix, and endocervical dendritic cell 
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subsets are poorly defined but many express CD11c, DC-SIGN, and more controversially CD14 
(8-13). Macrophages are found in the epithelium of the endocervix and the lamina propria of 
both the ecto- and endocervix, and express CD68 intracellularly and HLA-DR and CD14 on the 
cell surface (8). The functional characteristics of APCs in the human vagina are only beginning 
to be elucidated (13) and are still unknown in the endocervix.  
 Cervical and vaginal epithelial cells also play a critical role in maintaining the mucosal 
barrier, interacting with commensal microbiota, and influencing local immune cells including 
APCs (14, 15). Primary human genital epithelial cells are difficult to study ex vivo due to rapid 
loss of viability, but HPV16/E6E7 immortalized human epithelial cell lines derived from normal 
vaginal, endocervical, and ectocervical cell lines maintain the morphological and immunological 
characteristics of primary tissue and provide a simple and reproducible model (16). These cell 
lines retain the Toll-like receptor expression pattern of the primary tissue (17, 18) and produce 
cytokines such as CXCL8, CCL5, IL-1α, and IL-1β upon stimulation with microbial-associated 
molecular patterns (MAMPs) (19). Consequently, they have been used to test the inflammatory 
properties of particular commensal vaginal bacteria, viruses, microbicide products, and STIs 
(20-23). While these cell lines activate NF-κB with MAMP stimulation and bacterial co-culture 
(20, 24), the pathway leading to IL-1β secretion in these cells is unknown. 
 Here we elucidate several pathways by which genital antigen presenting cells and 
epithelial cells sense and respond to individual bacterial species and communities commonly 
found in young South African women. Additionally, using an epithelial cell–bacterial co-culture 
model, we demonstrate that CT4 bacteria are capable of directly inducing the secretion of pro-
inflammatory cytokines. 
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Figure 3.1 Assessment of antigen presenting cell frequency and phenotype in cervical 
cytobrushes. (A, B) CD14 (A) and CD11c (B) immunohistochemical staining of endocervical tissue. 
Scale bar: 50 µm. (C) Gating strategy for flow cytometric analysis. Fluorescence minus one controls 
were used to determine the positive gates for CD38, HLA-DR, CCR5, and CD25. (D) Comparing APC 
subset frequency between CT1/2 and CT4. 
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Results 
Genital antigen presenting cells from women with high diversity genital communities are 
activated by microbial products in vivo 
Antigen presenting cells (APCs) in the cervix are closely associated with the epithelium 
(Figure 3.1A and B) and sense microbes in conjunction with epithelial cells (25). Because the 
context in which APCs are stimulated can have important effects on their phenotype and ability 
to prime adaptive immune cells (1, 14), we performed phenotypic and transcriptional analyses 
on sorted APCs obtained by cervical cytobrush to understand bacterial sensing in situ. Due to 
the low frequency (10%) of participants with Lactobacillus crispatus dominance, we compared 
APCs from women in CT1 or CT2, who had gram-positive Lactobacillus dominance, to those in 
CT4, additionally excluding anyone with an active STI. Using a basic flow cytometry panel 
(Figure 3.1C), we saw no significant difference in the frequency of cervical APC subsets 
(CD11c+ dendritic cells or CD14+ monocyte/macrophages), with most APCs double positive for 
CD11c and CD14 (Figure 3.1D). 
However, we did observe significant differences in the APCs between CT1/2 and CT4 by 
digital gene expression analysis. 35 genes were significantly upregulated and 2 were 
downregulated in women with Prevotella dominant communities relative to those with 
Lactobacillus dominance (false discovery rate [FDR] <0.05; Figure 3.2). The genes upregulated 
in CT4 were enriched in NF-κB, Toll-like receptor, NOD-like receptor, and TNF-α signaling 
pathways. Gene set enrichment analysis revealed that 20 of the 35 genes upregulated in CT4 
APCs were shared with monocytes treated with a low dose of lipopolysaccharide (LPS, a TLR4 
agonist; q=6.16e-36) and 19 genes were shared with dendritic cells treated with LPS 
(q=1.11e-33). Ingenuity Pathway Analysis also identified LPS as the most likely upstream 
regulator to be activated in CT4 APCs (p=9.47e-26). These results are consistent with our 
bacterial pathway analysis using the microbial DNA shotgun sequences, which demonstrated 
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that LPS biosynthesis (ko00540) was the second most enriched pathway in the high 
inflammation samples compared to those with low inflammation.  
  
In addition to LPS, Ingenuity Pathway Analysis also predicted IFN-γ (p=6.31e-24), IL-1β 
(p=1.51e-23), and CSF2 (GM-CSF, p=6.74e-22) to be upstream regulators of the CT4 APCs, 
which is consistent with higher levels of IFN-γ and IL-1β in the CVLs of women with CT4. Also 
 
Figure 3.2 Transcriptional profiling suggests that CT4 bacterial products are sensed by 
cervical antigen presenting cells (APCs), which contribute to genital inflammation by 
producing a myriad of pro-inflammatory cytokines and critical T cell chemoattractants. (A) 
Heatmap of genes differentially expressed in cervical APCs from women with Lactobacillus 
dominant communities (>95% abundance) (from left to right: 2 in CT1, 3 in CT2) versus those with 
high Prevotella abundance (>25%) (n=5 in CT4). Women with STIs were excluded. Only genes 
with a false discovery rate < 0.05 are shown. Gene set enrichment analysis was used to determine 
statistically significant similarities with annotated gene sets. (B) PBMC APC levels of the same 
genes differentially regulated in cervical APCs, from the same women (matched PBMCs were not 
available for 2 women). If no transcripts were present for a given gene, the gene name was omitted 
from the heatmap.  
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consistent with the CVL cytokine measurements, CT4 APCs had significantly higher expression 
of many pro-inflammatory cytokine genes, such as IL1A (5.8-fold), IL1B (4.3-fold), TNF (6.5-
fold), IL10 (10.6-fold), IFNB1 (23.4-fold), IL23A (7.3-fold), and IL6 (8.9-fold), compared to CT1/2 
APCs (Figure 3.2A). Of relevance to cellular recruitment, CT4 APCs also upregulated the 
chemokines CCL4 (MIP-1b, a CCR5 ligand, 5.7-fold), CXCL9 (MIG, a CXCR3 ligand, 9-fold), 
and CCL8 (MCP-2, a CCR1 and CCR5 ligand, 6.3-fold). These transcriptional differences were 
not observed when comparing APCs from the peripheral blood of the same women (Figure 
3.2B). Thus, the transcriptional profile of cervical APCs indicates that they are responding to a 
CT4 bacterial product such as LPS and subsequently initiating acute inflammation and 
lymphocyte recruitment, and that these differences are not a reflection of systemic inflammatory 
activation. 
Identification of bacterial species that cause pro-inflammatory cytokine secretion in a 
vaginal epithelial cell co-culture model 
As CT4 seemed to contain bacterial species with LPS, we shifted our focus from 
interrogating the effects of communities to identifying the pro-inflammatory effects of particular 
bacterial taxa. To identify candidate bacteria to test in an in vitro system, we asked which 
bacteria were most highly correlated with inflammation in vivo. To select bacterial taxa to use in 
a multivariate model, we performed univariate Spearman correlations between cytokine PC1 
and each taxon found with over 0.1% abundance. The twelve taxa with highly significant 
correlations (p≤0.005) were included as predictor variables in the multivariate analysis. Since 
many taxa were highly correlated, the ridge method was used to correct for multicollinearity and 
revealed six genera significantly correlated with cytokine PC1: Fusobacterium, Aerococcus, 
Sneathia, Gemella, Mobiluncus, and Prevotella (Table 3.1). Since 16S rRNA amplicon 
sequencing cannot consistently identify bacteria at the species level, the previously performed 
whole-genome sequencing analysis was used to identify specific candidate species from these 
genera. 
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We used these candidates to test the causative relationship between individual bacterial 
species and genital inflammation with an in vitro epithelial cell co-culture assay. This model has 
previously been used to demonstrate the pro-inflammatory properties of Gardnerella vaginalis, 
Atopobium vaginae, and Prevotella bivia (20, 26). We co-cultured immortalized human vaginal 
epithelial cells with bacterial isolates and measured secreted pro-inflammatory cytokines in the 
supernatant. Consistent with our in vivo findings, Prevotella amnii, Mobiluncus mulieris, 
Sneathia amnii, and Sneathia sanguinegens induced higher levels of IL-1α, IL-1β, and IL-8 than 
Lactobacillus crispatus (Figure 3.3).  
Table 3.1 Determining which bacterial taxa are most 
highly correlated with pro-inflammatory cytokines levels. 
Ridge regression analysis with cytokine PC1 as the response 
variable and bacterial abundances as the predictor variables. 
The bacterial prevalence amongst the 94 subjects is also 
shown; taxa must have an abundance of at least 1% within a 
sample to be considered present. 
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Figure 3.3 Bacterial species highly correlated 
with pro-inflammatory cytokines in vivo also 
stimulate vaginal epithelial cells to produce the 
same cytokines in vitro. IL-1α, IL-1β, TNF-α, and 
IL-8 secretion by vaginal epithelial cells after in vitro 
application of 15 log10 CFU/cm2 of each bacterial 
species. MALP-2 (a TLR 2/4 agonist; 25nM) 
treatment was used as a positive control (value 
denoted by dashed line). P values were determined 
by a Dunnett test, compared to Lactobacillus 
crispatus. Data shown as mean and SEM, with two 
biological replicates. 
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Table 3.2. IL-1α, IL-1β, TNF-α, and IL-8 induced by in vitro application of bacterial species 
to vaginal epithelial cells. Prevotella amnii was only tested at 2 log10 CFU/cm2 due to difficulty 
with growing the bacteria. MALP-2 (25 nM) is used as a positive control. Data shown as mean ± 
SEM (performed in duplicate). 
  IL-1α (pg/ml) 
log10CFU/ 
cm2 
Lactobacillus 
crispatus 
Lactobacillus 
iners 
Aerococcus 
christensenii 
Mobiluncus 
mulieris 
Prevotella 
amnii 
Sneathia 
amnii 
Sneathia 
sanguinegens 
15 53 ± 5.0 67 ± 13 5 ± 0 121.5 ± 17.5 n/a 292.5 ± 13.5 386.5 ± 3.50 
12 51.5 ± 1.50 56.5 ± 2.50 2.5 ± 1.5 66 ± 4.0 n/a 263 ± 71.0 252.5 ± 12.5 
8 48 ± 1.0 46 ± 6.0 6 ± 0 49.5 ± 5.50 n/a 87.5 ± 13.5 96.5 ± 2.50 
5 56.5 ± 6.5 43.5 ± 2.5 0.5 ± 0.5 46.5 ± 4.50 n/a 48.5 ± 1.50 70.5 ± 10.5 
2 52.5 ± 3.5 45 ± 3.0 18.5 ± 16.5 46.5 ± 1.50 83 ± 28 47 ± 2.0 43.5 ± 1.5 
          IL-1β (pg/ml) 
log10CFU/
cm2 
Lactobacillus 
crispatus 
Lactobacillus 
iners 
Aerococcus 
christensenii 
Mobiluncus 
mulieris 
Prevotella 
amnii 
Sneathia 
amnii 
Sneathia 
sanguinegens 
15 6.0 ± 3.0 21.5 ± 2.5 5.5 ± 2.5 18.5 ± 6.5 n/a 77.5 ± 17.5 135 ± 3.0 
12 3.0 ± 0.0 8.0 ± 0.0 4.0 ± 1.0 5.0 ± 1.0 n/a 37 ± 0.0 65 ± 21.0 
8 5.5 ± 0.5 4.0 ± 2.0 3.0 ± 1.0 3.5 ± 1.5 n/a 16.5 ± 3.5 20 ± 3.0 
5 4.5 ± 0.5 3.0 ± 0.0 5.0 ± 0.0 3.5 ± 0.5 n/a 4.0 ± 1.0 4.5 ± 0.5 
2 4.0 ± 0.0 2.5 ± 0.5 3.0 ± 1.0 2.0 ± 0.0 5.5 ± 1.5 3.0 ± 0.0 3.5 ± 1.5 
          TNF-α (pg/ml) 
log10CFU/
cm2 
Lactobacillus 
crispatus 
Lactobacillus 
iners 
Aerococcus 
christensenii 
Mobiluncus 
mulieris 
Prevotella 
amnii 
Sneathia 
amnii 
Sneathia 
sanguinegens 
15 4.5 ± 0.5 25.5 ± 2.5 5.0 ± 0.0 263.5 ± 184.5 n/a 76 ± 40 26 ± 14 
12 2.5 ± 0.5 11 ± 0 2.5 ± 1.5 53.5 ± 5.50 n/a 
156.5 ± 
137.5 107 ± 59.0 
8 0 ± 0.5 9.0 ± 1.0 6.0 ± 0.0 28.5 ± 22.5 n/a 10 ± 4.0 20 ± 2.0 
5 0.5 ± 0.5 4.0 ± 1.0 0.5 ± 0.5 5.5 ± 1.5 n/a 0 ± 0 18.5 ± 6.5 
2 0.5 ± 0.5 19 ± 12 18.5 ± 16.5 3 ± 2.0 69 ± 11 2.5 ± 0.5 4.0 ± 2.0 
          IL-8 (pg/ml) 
log10CFU/
cm2 
Lactobacillus 
crispatus 
Lactobacillus 
iners 
Aerococcus 
christensenii 
Mobiluncus 
mulieris 
Prevotella 
amnii 
Sneathia 
amnii 
Sneathia 
sanguinegens 
15 581 ±  1.00 4,173 ± 167 645 ± 8.00 10,100 ± 875 n/a 13,800 ± 744 11,300 ± 578 
12 363.5 ± 2.50 1,690 ± 10.0 364 ± 12.0 2,580 ± 93.5 n/a 8,560 ± 505 10,900 ± 205 
8 339.5 ± 0.500 568 ± 7.00 314.5 ± 4.50 481 ± 43.5 n/a 2,060 ± 47.0 6,490 ± 121 
5 360.5 ± 3.50 303 ± 1.00 315.5 ± 3.50 302 ± 17.0 n/a 403 ± 19 837 ± 58.5 
2 344.5 ± 28.5 301 ± 13.0 312.5 ± 14.5 289 ± 5.00 1,290 ± 82.5 275 ± 4.0 305 ± 19.0 
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Prevotella, the genus consistently present in CT4, was able to induce significant cytokine 
secretion even at an input CFU as low as 2 log10 (Table 3.2). Additionally, L. iners induced 
moderate IL-8 secretion, consistent with reports that it can have moderate pro-inflammatory 
activity, while L. crispatus and Aerococcus christensenii did not elicit any cytokine secretion 
relative to the absence of bacteria. Low levels of TNF-α were detected in response to these 
bacteria. These data suggest that epithelial cells sense cervicovaginal bacteria in a species 
specific manner and contribute to the observed pro-inflammatory cytokines found in women in 
CT4.  
Determining MAMPs that induce inflammasome activation and IL-1β  release from cervical 
epithelial cells 
 IL-1β is the pro-inflammatory cytokine most consistently found to be elevated in 
cervicovaginal lavages of women with bacterial vaginosis (27-32). Additionally, we found that 
CVLs from women with CT4 contain an average of 70-times the concentration of IL-1β than 
those from CT1 (Figure 2.4), and several CT4 bacterial species are capable of inducing IL-1β 
secretion from vaginal epithelial cells (Figure 3.3). However, surprisingly little is known about 
the sensing mechanisms leading to IL-1β release in the genital tract. Given that the secretion of 
active IL-1β is tightly regulated by caspase-1 and that we found several bacterial species that 
induce IL-1β secretion from epithelial cells (Table 3.2), we hypothesized that the inflammasome 
is activated by BV and CT4 associated bacteria in epithelial cells of the lower female 
reproductive tract.  
 We first asked which microbial-associated molecular patterns lead to IL-1β secretion in 
cervicovaginal epithelial cells. We utilized immortalized human ectocervical (Ect1/E6E7) and 
endocervical (End1/E6E7) epithelial cells (16) that were previously shown to express TLR1, -2, -
3, -5, -6, -7, and -9, but neither TLR4 nor MD2 (17, 18). End1 and Ect1 cells were treated with 
poly(I:C) (dsRNA analog, TLR3 and RIG-I agonist), FSL-1 (Pam2CGDPKHPKSF, TLR2/6 
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agonist), Imiquimod (TLR7 agonist), ODN2006 (TLR9 agonist), and LPS (TLR4 agonist) for 8 h 
followed by a 50-minute ATP stimulation. The THP-1 human monocytic cell line is known to 
produce copious amounts of IL-1β upon stimulation and were included as a positive control 
(data not shown.) We found significant IL-1β secretion from Ect1 and End1 cells only in 
response to ATP primed by poly(I:C), which activates both TLR3 and RIG-I (Figure 3.4). End1 
cells also secreted IL-1β in response to poly(dA:dT) (5 µg/ml), a repetitive synthetic double-
stranded DNA sequence that is indirectly sensed by RIG-I (33). The lack of IL-1β release in 
response to nigericin (10 µM), a potassium ionophore, indicates the inability of End1 and Ect1 
cells to assemble the NLRP3 inflammasome independent of TLR priming. Staurosporin (1 µM), 
a classical inducer of the cell intrinsic apoptotic pathway, was used to measure non-specific IL-
1β released from dying cells.  
 
We then asked whether caspase-1 is activated in End1 and Ect1 cells after ATP 
treatment. Caspase-1 activation was measured using a cell-permeant fluorescent probe that 
covalently bonds specifically to active caspase-1 via a FAM-YVAD-FMK motif. Necrotic cells 
 
Figure 3.4 IL-1β secretion is induced by Poly(I:C) in both Ect1 and End1 cells. End1 and Ect1 
cells were stimulated with poly(I:C) (TLR3/ RIG-I agonist), FSL-1 (Pam2CGDPKHPKSF; TLR2/6 
agonist), LPS (lipopolysaccharide; TLR4 agonist), ODN2006 (human TLR9 agonist), imiquimod (TLR7 
agonist), Poly(dA:dT)/Lyovec (complexed dsDNA; AIM2/RIG-I agonist), nigericin (NLRP3 inducer), 
ATP (NLRP3 inducer), or staurosporin (classical apoptosis inducer). IL-1β was detected from cell-free 
supernatants of A) Ect1 and B) End1 cells using an ELISA (R&D Systems). Assays were performed in 
duplicate and the data is representative of two independent experiments. 
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were identified by propidium iodide and excluded. The THP-1 human monocytic cell line has 
previously been shown to robustly activate caspase-1 when stimulated with PMA and ATP and 
was included as a positive control. We detected active caspase-1 in End1 cells stimulated by 
ATP after poly(I:C) priming, and both End1 and Ect1 cells stimulated by ATP after ODN2006 
priming, but not by FSL-1, Imiquimod, or LPS (Figure 3.5). End1 cells tended to have more 
caspase-1 activation to a given stimulus compared to Ect1 cells.  
As poly(I:C) provided both adequate priming for IL-1β secretion and caspase-1 
activation,  we confirmed expression of the poly(I:C) sensors RIG-I and TLR3 in Ect1 and End1 
cells. RIG-I is highly expressed in both End1 and Ect1 cells, and upregulated 3-10 fold upon 
poly(I:C) treatment (Figure 3.6A,B). TLR3 was expressed at moderate levels at baseline in both 
cell types, and upregulated four-fold in End1 cells after poly(I:C). Additionally, both Ect1 and 
End1 cells weakly expressed NLRP3, the NOD-like receptor that is triggered by ATP, and was 
upregulated after poly(I:C) stimulation (Figure 3.6C). Thus, cervical epithelial cells express 
several sensors of poly(I:C), and further experiments would be necessary to determine the 
dominant sensing pathway. 
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Figure 3.5 Caspase-1 is activated by poly(I:C) in End1 cells and ODN2006 in End1 and Ect1 
cells. (A) Representative flow cytometric plots of End1 cells that were treated with a TLR ligand and 
ATP, then stained with a FAM-YVAD-FMK fluorescent probe to assess capase-1 activation and 
propidium iodide to exclude necrotic cells. Necrotic cells were excluded from further caspase-1 
analysis. (B) Comparison of Ect1 and End1 caspase-1 activation in response to TLR ligands – 
poly(I:C) (TLR 3/ RIG-I), FSL-1 (Pam2CGDPKHPKSF) (TLR2/6), LPS (TLR4), Imiquimod (TLR7), or 
ODN2006 (CpG) (TLR9) – for 8 h followed by ATP stimulation for 50 min. Assays were performed in 
duplicate and the data is representative of two independent experiments. 
 
Figure 3.6 TLR3, RIG-I and NLRP3 are expressed at baseline in End1 and Ect1 cells and 
upregulated by Poly(I:C). End1 and Ect1 cells were stimulated with poly(I:C) (1 ug/ml) for 24 h and 
qPCR was used to quantify the amount of (A) RIG-I, (B) TLR3, and (C) NLRP3 transcripts relative to 
an unstimulated control and GAPDH. All three genes were expressed in the unstimulated control and 
upregulated after poly(I:C) treatment. 
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Discussion 
 We show here that CT4 bacterial community members are directly capable of inducing 
the production of pro-inflammatory cytokines, and provide evidence for two distinct CT4 
bacterial sensing mechanisms by cervical APCs and epithelial cells. Cervical APCs specifically 
appear to respond to LPS via Toll-like receptor 4 signaling, contributing to genital inflammation 
through NF-κB activation and recruitment of lymphocytes by chemokine production. This was 
consistent with the bacterial pathway analysis that demonstrated that LPS biosynthesis was 
highly enriched in bacterial communities from women with high genital inflammation. In contrast, 
cervical epithelial cells are insensitive to LPS but both activate caspase-1 and produce IL-1β in 
response to a synthetic dsRNA agonist.   
 
Bacterial sensing by genital antigen presenting cells 
Transcriptional analyses on APCs isolated from cervical cytobrushes revealed that APCs 
from women with high Prevotella abundance demonstrate a marked response to LPS, as well 
as to IFN-γ and IL-1β. This likely reflects both the pathogenic stimulation by gram-negative 
bacteria and bacterial responses by neighboring cells like epithelial cells, T cells, and natural 
killer cells. CT4-associated APCs upregulate genes encoding the key cytokines comprising the 
CT4 cytokine signature: IL-1α, IL1-β, TNF, and IL-10. Two long intergenic non-coding RNAs, 
LINC00515 and LINC00664, were also upregulated in CT4 APCs, and while their function is 
currently unknown their potential post-transcriptional activities would be interesting to 
investigate in future studies. Perhaps of greatest importance to HIV acquisition risk, CT4 APCs 
were also more activated and mature, with higher expression of CD80, ICAM-1, MHC II, and 
miR-155, and could be contributing to both T cell priming and effector function control (34, 35). 
This APC activation may be driving the modest but significant T cell infiltration seen in the 
cervical cytobrushes of women with high pro-inflammatory cytokine levels (Figure 2.7), which 
would have significant implications for HIV acquisition risk. 
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Direct induction of pro-inflammatory cytokines by CT4 bacteria 
 Within CT4, we found that Sneathia sanguinigens, Sneathia amnii, Mobiluncus mulieris, 
and Prevotella amnii are capable of inducing the secretion of IL-1α,  IL-1β, and IL-8 from human 
vaginal epithelial cells in vitro. Aerococcus christensenii was highly associated with inflammation 
in vivo but did not induce cytokine secretion in vitro, possibly due to the particular bacterial 
isolate that we tested or because it is merely well-adapted to surviving in inflamed tissue but not 
a primary driver of inflammation. We did not test Fusobacterium spp. due to difficulty with 
acquiring the proper species, but Fusobacterium nucleatum has been shown to be pro-
inflammatory and tumorigenic in the gut (36). Overall, several CT4 bacteria are capable of 
directly inducing pro-inflammatory cytokine production from epithelial cells in vitro. It would be 
worthwhile to extend these co-culture analyses to more complex systems such as those using 
cervical explants and mixed multilayer cultures of epithelial cells with monocyte-derived 
macrophages. 
IL-1β  production from cervical epithelial cells 
 Surprisingly, poly(I:C) was the only Toll-like receptor stimulus that provided both 
adequate priming for IL-1β secretion and caspase-1 activation in cervical epithelial cells. 
Poly(I:C) is a synthetic analog of double-stranded RNA and is thus commonly thought of as a 
virus-associated molecular pattern. However, dsRNA has also recently been shown to be 
produced by symbiotic bacteria, and is capable of inducing a protective immune response in the 
gut (37). It is unclear why symbiotic bacteria produce dsRNA, but it may involve CRISPR 
targeting. Interestingly, the bacterial dsRNA concentration varies amongst bacterial species and 
growth conditions. Gut lactic-acid producing bacteria have more dsRNA than pathogenic gut 
bacteria like Salmonella and Listeria, and the dsRNA concentration increases when bacteria are 
grown in high NaCl stress conditions (37). While the dsRNA concentration in vaginal 
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Lactobacilli, Gardnerella and Prevotella spp. is unknown, we hypothesize that it is highest in 
Prevotella spp. and will pursue this question in future studies. 
 In conclusion, a plethora of studies have shown associations between bacterial 
vaginosis and cervicovaginal lavage concentrations of IL-1β and a handful of other pro-
inflammatory cytokines. Here, we make the important mechanistic advancement of individually 
interrogating the bacterial species comprising the pro-inflammatory bacterial community that we 
identified in women and determining which are capable of directly causing cytokine production. 
We determine the bacterial components that are sensed by the local antigen presenting cells 
and epithelial cells, and propose a novel mechanism, that of dsRNA sensing, for the production 
of genital pro-inflammatory cytokines. 
Materials and Methods 
Immunophenotyping of cervical cytobrush samples 
 Cervical and peripheral blood cells were phenotyped using monoclonal antibodies to the 
following human proteins in multiparameter FACS analysis: CD4+5 (HI30), CD3 (UCHT1), 
CD8+ (SK1), HLA-DR (G46-6), CD38 (HIT2), CD25 (2A3), CCR5 (2D7), CD11c (B-ly6), CD14 
(M5E2), CD19 (HIB19) from BD Biosciences; and CD4+ (S3.5) from Life Technologies. All 
antibodies were titrated before use. Viable cells were identified by a LIVE/DEAD violet dead cell 
stain (Life Technologies). Cells were passed through a 70µm filter prior to analysis on the FACS 
Aria III (BD Biosciences). Rainbow beads (Spherotech) were used to ensure comparable 
fluorescence measurements between experiments. There were 84 women for whom we had 
both cervical cellular phenotyping information and CVL cytokine measurements. 
Cells were sorted directly into TRIzol (Life Technologies), vortexed vigorously, and 
stored at -80°C. Data were processed using FlowJo software (Treestar). CD4+ T cells were 
gated by: FSC vs. SSC, singlets, live CD19-, CD4+5+, CD3+, CD4+ CD8-. Antigen presenting 
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cells were gated by: FSC vs. SSC, singlets, live CD19-, CD4+5+, HLA-DR+ CD3-, and CD11c+ 
or CD14+.   
Immunohistochemistry 
Excess surgical tissue deemed histologically normal by a certified pathologist was 
acquired through Massachusetts General Hospital (IRB protocol 2010P000632). CD14 (1:200, 
Clone 7, Abcam) staining was performed on formalin-fixed, paraffin-embedded endocervical 
tissue sections after antigen retrieval in 1X DIVA Decloaker (Biocare Medical) for 2 minutes. 
CD11c (1:50, Clone B-ly6, BD) staining was performed on acetone-fixed frozen endocervical 
tissue sections. After primary antibody incubation, a secondary HRP-labeled goat anti-mouse 
was applied (EnVision+ System-HRP, Dako). The stain was developed with DAB and 
enhancement (Dako), followed by a hematoxylin counterstain.  
RNA extraction from sorted cells 
Briefly, Gen-Elute linear polyacrylamide (Sigma) was added to the RNA in TRIzol, 
followed by the addition of 0.2 volumes of chloroform and vortexing. After centrifuging at 
14,000xg for 5 minutes, the aqueous phase was transferred to a clean tube. The remaining 
steps were performed as described above (in “Nucleic acid extraction from cervical swabs”), 
with final nucleic acid reconstitution in 5µL of nuclease-free water. RNA quality and quantity 
were assessed using the Bioanalyzer (Agilent) and RINs were consistently above 9. 
Transcriptional analysis of sorted cells 
 The RNA-seq libraries were prepared according to the Single Cell RNA Barcoding and 
Sequencing method originally developed for single cell RNA-seq (SCRB-seq (38)) and adapted 
to extracted total RNA. Briefly, Poly(A)+ mRNA from extracted total RNA were converted to 
cDNA decorated with universal adapters, sample-specific barcodes and unique molecular 
identifiers (UMIs) using a template-switching reverse transcriptase. Decorated cDNA from 
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multiple samples were then pooled, amplified and prepared for multiplexed sequencing using a 
modified transposon-based fragmentation approach that enriched for 3’ ends and preserved 
strand information. 
 All second sequence reads were aligned to a reference database consisting of all human 
RefSeq mRNA sequences (obtained from the UCSC Genome Browser hg19) and the human 
hg19 mitochondrial reference sequence using bwa version 0.7.4 with non-default parameter “-l 
24”. Digital gene expression (DGE) profiles were then generated by counting, for each 
microplate well and RefSeq gene, the number of unique UMIs associated with that gene in that 
well. Python scripts implementing the alignment and DGE derivation are available from the 
authors upon request. 
 Digital gene expression values were analyzed using the edgeR package (39).  
When analyzing the digital gene expression values using EdgeR, counts were normalized by 
weighted trimmed mean of M-values and significance was tested with a general linearized 
model. 
Bacterial strains and colonization assays 
 Isolates were obtained from the Culture Collection University of Göteborg (Sweden), the 
American Type Culture Collection (ATCC, Manassas, VA), and collaborators. The Lactobacillus 
crispatus isolate was originally collected from a vaginal swab from a healthy woman (40).  
Lactobacillus iners (28746), Aerococcus christensenii (28831), Peptostreptococcus (44095), 
Prevotella amnii (53648), Sneathia amnii (64370), and Sneathia sanguinegens (41628) were 
acquired from the Culture Collection University of Göteborg (Sweden). Mobiluncus mulieris 
(35243) was acquired from the American Type Culture Collection (ATCC, Manassas, VA). 
Bacteria were cultured on Brucella agar under anaerobic conditions and allowed to colonize 
human vaginal epithelial cells at 2 to 15 log10 CFU/cm2 for 24h under anaerobic conditions as 
previously described (20). IL-1α, IL-1β, IL-8, and TNF-α were measured in 24h supernatants 
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using a Meso Scale Discovery multiplex electrochemiluminescence assay (20). MALP-2 
(macrophage-activating lipopeptide-2, a TLR 2/4 agonist; 25nM) was used as a positive control. 
Atopobium vaginae, Gardnerella vaginalis, Prevotella bivia, and Lactobacillus gasseri were not 
tested due to our prior results indicating that all induce significant inflammatory responses 
except L. gasseri (previously referred to as L. acidophilus) (23). 
Epithelial cell in vitro stimulation 
 Ect1/E6E7 and End1/E6E7 cells were grown to 80% confluence, and were stimulated 
with either poly(I:C) (1 µg/ml of LMW, 1 µg/mL of HMW), FSL-1 (100 ng/ml), LPS (100 ng/ml), 
ODN2006 (5 µM), or imiquimod (1 µg/ml) for 7.5 hours, then ATP (5 mM) was added for an 
additional 50 minutes (all reagents from Invivogen). Alternatively, cells were treated with 
poly(dA:dT)/Lyovec (5 µg/ml, Invivogen), nigericin (10 µM, Invivogen), staurosporin (1 µM, 
Sigma). As a positive control, THP-1 cells at a concentration of 2-5 x 105 cells/mL were 
differentiated into macrophages by an 18-hour phorbol myristate acetate (PMA, 100 ng/ml, 
Sigma) treatment, treated with LPS (100 ng/ml) for 7.5 hours and then ATP for another 50 
minutes. Supernatants were collected and stored at -80C, and then adhered cells were either 
trypsinized and resuspended in low Ca2+ keratinocyte serum-free media, or washed with PBS 
and lysed in RLT buffer with β-mercaptoethanol (Qiagen).  
Caspase-1 activation and IL-1β measurements 
Caspase-1 activation was assessed using the FLICA 660 Caspase-1 Assay kit 
(Immunochemistry), following the manufacturer’s protocol except using a 1:120 dilution, which 
was determined to provide an optimal signal to noise ratio by titration. Dead cells were identified 
by staining with propidium iodide immediately prior to flow cytometric analysis (4 Laser LSR 2, 
BD). Soluble IL-1β measurements were performed on cell-free supernatants using an ELISA 
(R&D Systems). 
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Epithelial cell RNA extraction and qPCR 
RNA was extracted using an RNeasy Micro kit (Qiagen) and cDNA was made using a 
high capacity cDNA reverse transcription kit (Life Technologies). qPCR was performed using 
published primers for human RIG-I (F:CTCTGCAGAAAGTGCAAAGC, 
R:GGCTTGGGATGTGGTCTACT), TLR3 (F: GTGCCAGAAACTTCCCATGT, R: 
CTTCCAATTGCGTGAAAACA), NLRP3 (F: AAAGAGATGAGCCGAAGTGGG, R: 
TCAATGCTGTCTTCCTGGCA), and GAPDH (all from (41) except TLR3 from (42)) using the 
Brilliant II SYBR Green qPCR kit per manufacturer instructions.  
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Introduction 
Since their introduction in the 1960s, hormonal contraceptives have empowered women 
to pursue advanced educational and occupational opportunities by preventing unwanted 
pregnancies while reducing their risk of maternal mortality (1, 2). Hormonal contraceptives can 
be taken discreetly and, unlike condoms, do not require the cooperation of the male partner. 
They also come in extremely convenient forms: long-acting injectable progestin-only 
contraceptives (IPCs) are administered with a single injection every 2-3 months and are over 
99% effective. IPCs, including depot medroxyprogesterone acetate (DMPA, marketed as Depo 
Provera) and norethindrone enanthate (NET-EN, marketed as Nuristerate), are the favored form 
of contraception in sub-Saharan Africa (3-5). Especially considering all of their advantages, it is 
most regrettable that IPCs, like other female-controlled contraceptives, not only fail to provide 
protection against STIs, but also have been found to be associated with a significantly elevated 
risk of acquiring HIV in some epidemiological studies (6-11).  
In areas like sub-Saharan Africa with a high HIV prevalence, the question of whether 
and how IPCs affect HIV acquisition risk is one of utmost importance. Decisions regarding the 
withdrawal of IPCs from clinics in these areas must carefully balance the risk of HIV acquisition 
with the aforementioned risks of unwanted pregnancy, maternal mortality, and limiting women’s 
career opportunities. The epidemiological studies driving these decisions are complicated by 
behavioral and demographic confounders that may mask a true biological effect of IPCs on 
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acquisition (12, 13), including that women using IPCs are more likely to be older and in stable 
relationships and less likely to use condoms than women not using a family planning method. 
Furthermore, they cannot establish whether association with increased HIV acquisition risk – as 
high as 4-fold (14) but on average 1.4 fold – represents a causal effect of the contraceptive or is 
simply associated with contraceptive use because of sexual behaviors that may both inform 
contraceptive choice and HIV acquisition risk. While progestins have been shown to have a 
multitude of effects on immune function in vitro (15-19), it is still unclear how these effects 
manifest in vivo to modulate HIV acquisition risk.  
Understanding how IPCs biologically modify the female genital tract (FGT) in vivo can 
provide a mechanism by which IPCs could lead to increased HIV acquisition risk. We therefore 
assessed alterations in the FGT immune environment in the context of IPC use in a cohort of 
young women at high risk of acquiring HIV, attempting to draw a biological link between IPC use 
and the epidemiological association with increased HIV acquisition risk. 
Results 
Contraceptive usage amongst FRESH study participants 
  We first determined which contraceptive methods were utilized by the FRESH 
participants. Consistent with previous studies, of the 74% of participants who reported having 
vaginal sex in the past 30 days, only 39% 
reported always using a condom. Of the 41% of 
women in the cohort who used some form of 
non-condom contraception, herein referred to as 
family planning, 87% of participants were using 
an IPC (Figure 4.1). Three times as many 
women used DMPA than Nuristerate. The 
 
 
Figure 4.1 Family planning methods utilized by 
the FRESH cohort (n=253). 
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remaining women on family planning used oral contraceptive pills (7% of family planning users), 
an intrauterine device, or tubal ligation. 
 IPC use was self-reported but verified using two methods: by measuring plasma 
hormone levels in a randomly selected subset of 222 women, and by directly measuring plasma 
medroxyprogesterone levels in a subset of women. As expected, women using an IPC had 
significantly suppressed progesterone (p<0.001) and estradiol (p<0.0001) concentrations 
(Figure 4.2), with only two out of 84 IPC users demonstrating plasma progesterone levels within 
the expected range for a woman in the luteal phase. There were no differences in progesterone 
or estradiol levels amongst women using DMPA and Nuristerate. Of the women who were not 
using family planning, 129 were sampled during the follicular phase, as indicated by a 
progesterone concentration of 0.3 ng/mL or less, and 77 were sampled during the luteal phase, 
with a progesterone concentration at 1.2 ng/mL or more. Thus, we confirm that women using an 
IPC have suppressed estradiol and progesterone production, and self-reports appear to 
accurately reflect hormonal contraceptive usage.  
 
 
Figure 4.2 Plasma progesterone and estradiol concentrations in women not using family planning 
(n=114), using DMPA (n=84), or using Nuristerate (n=24). (A) Expected progesterone ranges for the 
follicular and luteal phases of menstruating women are indicated in pink and green shading, respectively. 
(B) Expected estradiol ranges for normally menstruating women are indicated by blue shading. Medians 
are shown with a horizontal line. P values determined by Kruskal-Wallis test with a Dunn’s post test. *** 
indicates p<0.001; **** indicates p<0.0001. Single timepoints were included for 173 women and multiple 
timepoints for 49 women. 
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 The second verification that we performed was to use mass spectroscopy to directly 
measure the active compound of DMPA, called medroxyprogesterone acetate (MPA), in the 
plasma of a randomly selected subset of women who self-reported using DMPA, Nuristerate, or 
not using family planning. Of the women who reported using DMPA, 41 out of 44 (93%) had 
detectable MPA levels, consistent with using DMPA. Two of three without detectable MPA 
reported receiving their first injection three months before, thus the drug levels may have 
diminished by the time of sampling. One out of nine women who reported using Nuristerate had 
detectable DMPA, indicating that the participant misreported her contraceptive use. Finally, one 
out of eight women who denied using family planning had detectable DMPA. Thus, self-reports 
provide a fairly accurate account of contraceptive usage. 
Next we asked whether there were differences in demographic or behavioral risk factors 
between women using IPCs compared to women not using family planning. In univariate 
analysis, statistically significant differences were observed in the age of the participant (IPC 
users were one year older on average, p=0.0011, Mann-Whitney test), the age difference 
between the participant and their current sexual partners (the difference was one year greater 
for IPC users, p=0.0124, Mann-Whitney test), and the number of vaginal sex episodes in the 
past seven days (IPC users reported one more sexual act, p=0.0022, Mann-Whitney test) 
(Table 4.1). No differences were seen in condom use, anal sex frequency, casual partner count, 
STI frequency, or bacterial vaginosis frequency. Thus, despite the narrow age range dictated by 
the study enrollment criteria, women using IPCs tended to be slightly older with slightly older 
partners and more sexually activity. 
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Increased HIV acquisition risk amongst women using IPCs 
 We next asked whether women using IPCs had higher rates of HIV acquisition. Despite 
intensive counseling and education, the HIV incidence in the cohort is approximately 7 per 100 
person-years, corresponding to 15 women becoming infected by the time of analysis. Strikingly, 
in our study IPC users had a 5.5-fold higher risk of becoming infected with HIV than women not 
using family planning (p=0.0031, 95% CI: 1.733 – 16.80, Log-rank test) (Figure 4.3A). IPC use 
Table 4.1 Demographic, sexual behavior and sexual health characteristics of FRESH participants who 
use injectable progestin-only contraceptive (IPCs) versus those who do not use a non-condom family 
planning method. Data are presented as n/N (%) or median (IQR). *P-values are determined by Fisher’s exact 
test for categorical data and by Mann-Whitney for continuous data.  
    
Overall 
(N = 262)   
IPC 
(N = 95) 
No Family 
Planning 
(N = 141)   p-value* 
Sexual demographics               
Age of participant 
            Mean 
 
20.8 
 
21.2 20.5 
       Median (range) 
 
21 (18-24) 
 
21 (18-24) 20 (18-24) 
 
p=0.0011 
Age difference between participant and current 
sexual partner 
            Mean 
 
3.5 
 
4 3.2 
       Median (range) 
 
3 (-4, 17) 
 
4 (-2, 14) 3, (-4, 17) 
 
p=0.0124 
Sexual behavior   
    
    
Condom use in past 30 days-- no./total no. (%) 
            Always 49/235 (20.8) 
 
20/93 (21.5) 27/130 (20.8) 
 
p=0.5526 
     Sometimes 78/235 (33.2) 
 
33/93 (35.5) 40/130 (30.8) 
      Never 47/235 (20.0) 
 
23/93 (24.7) 20/130 (15.4) 
      Not applicable (no sex) 61/235 (26.0) 
 
17/93 (18.3) 43/130 (33.1) 
  Vaginal sex episodes in past 7 days 
            Mean 
 
0.54 
 
0.67 0.45 
       Median (range) 
 
0 (0, 4) 
 
1 (0, 3) 0 (0, 4) 
 
p=0.0022 
Vaginal sex episodes in past 30 days 
            Mean 
 
2.3 
 
2.6 2.1 
       Median (range) 
 
2 (0, 18) 
 
2 (0, 18) 2 (0, 12) 
 
p=0.0733 
Anal sex in past 30 days -- no./total no. (%) 
 
5/237 (2.0) 
 
1/92 (1.1) 3/133 (2.2) 
 
p=0.6466 
Casual or new sex partner in past 30 days 
 
2/227 (0.8) 
 
1/88 (1.1) 1/128 (0.7) 
 
p=1.000 
Sexual health-- no./ total no. (%)   
    
    
Neisseria gonorrhea 
 
12/226 (5.3) 
 
3/92 (3.3) 8/122 (6.6) 
 
p=0.3581 
Chlamydia trachomatis 
 
25/223 (11.2) 
 
8/92 (8.7) 17/119 (14.3) 
 
p=0.3902 
Mycoplasma genitalium 
 
18/226 (8.0) 
 
4/92 (4.3) 14/122 (11.5) 
 
p=0.0817 
Trichomonas vaginalis 
 
9/226 (4.0) 
 
3/92 (3.3) 5/122 (4.1) 
 
p=1.000 
HSV-1 
 
1/226 (0.4) 
 
0/92 (0) 1/122 (0.8) 
 
p=1.000 
HSV-2 
 
6/226 (2.6) 
 
2/92 (2.2) 4/122 (3.3) 
 
p=0.7017 
Bacterial vaginosis (score ≥7) 
 
39/220 (17.7) 
 
12/89 (13.5) 26/119 (21.8) 
 
p=0.1479 
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remained significant even after the covariates of the number of sexual acts in the past seven 
days and the age difference between the participant and the partner were incorporated into a 
Cox proportional hazards model (HR: 4.87, 95% CI: 1.290 - 18.403, p=0.0195). When IPCs 
were considered individually, Nuristerate users were at greater risk of HIV acquisition compared 
to those not on family planning (p<0.0001, HR: 13.2, 95% CI: 19.58 to 1584, Log-rank test) than 
DMPA users (p=0.0730, HR: 3.861, 95% CI: 0.8821-16.90, Log-rank test) (Figure 4.3B). Thus, 
we found that IPC users were five times more likely to acquire HIV than women not on family 
planning, and that Nuristerate users were at greater risk than DMPA users. 
 
IPC users have a higher frequency of activated HIV target cells in the endocervix 
  We next sought to determine immunological correlates of IPC use that may explain the 
association of IPCs with HIV infection. An important determinant of HIV acquisition risk is the 
frequency of HIV target cells at the mucosal site of exposure, which in women is thought to 
primarily be CCR5+ CD4+ T cells in the cervix (20-22). To test the hypothesis that IPCs 
increase target cell frequency at the superficial layers of the cervix, we performed FACS 
analysis on freshly collected matched cervical cells and peripheral blood. Because IPCs affect  
   
 
Figure 4.3 Kaplan-Meier curve comparing HIV acquisition rates amongst (A) all IPC users (B) 
and Nuristerate and DMPA users separately, compared to those not using a family planning 
method. The P value was determined by a log-rank test. 
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Figure 4.4 IPC use is associated with increased cervical HIV target cell frequency. Controlling for 
low endogenous progesterone level, injectable contraceptive use correlates with (A) a higher 
frequency of HIV target cells (defined as CD4+CCR5+ T cells) as a percentage of live CD4+5+ 
immune cells, (B) a higher proportion of CD4+ T cells expressing CCR5, and (C,D) higher CCR5 
expression on CD4+ T cells from the cervix but not the blood. Representative flow cytometry plots of 
CCR5 expression on CD4+ T cells are shown in (C), where the red histogram indicates a woman 
using an IPC, blue indicates a woman who is not using family planning (FP), and green with gray 
shading represents the fluorescence-minus-one control of background fluorescence. Only cytobrushes 
with over 500 live CD4+5+ cells were included in the analysis. 
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endogenous hormone levels (Figure 4.2) and endogenous progesterone may have its own 
effects on immune function, we controlled for progesterone levels below 0.3 ng/mL in the 
analysis, thus comparing women on IPCs to those in the follicular phase of the normal 
menstrual cycle. Additionally, we assessed DMPA and Nuristerate together as IPCs to ensure 
adequate sample sizes to uncover differences. We found significantly higher frequencies of HIV 
target cells as a percentage of live CD4+5+ cells in cervices of women using IPCs than those 
not using family planning (p=0.0241), though we did not find differences in the blood (Figure 
4.4A). There was no difference in the number of live cervical CD4+5+ cells recovered from the 
cytobrushes in the two groups. Additionally, the cervical CD4+ T cells of IPC users had higher 
CCR5 expression on the cell surface, as measured by the proportion of CD4+ T cells 
expressing CCR5 (p=0.0048, Figure 4.4B) and the median fluorescent intensity of CCR5 
staining (p=0.0157, Figure 4.4D). The proportion of CD4+ T cells expressing CCR5 is on 
average 10-fold lower in the peripheral blood than the cervix, and we did not detect significant 
differences in the CCR5 expression on peripheral blood CD4+ T cells between women using an 
IPC and in the follicular phase (Figures 4.4B-D). Thus, we found that IPC users have higher 
CCR5 expression on cervical CD4+ T cells, thereby increasing the number of HIV-susceptible 
target cells at the mucosal site of HIV exposure. 
 Because activated target cells produce more viral particles per cell than resting target 
cells (23, 24), which may accelerate viral dissemination (25), we next assessed target cell 
activation using three well-established cell surface markers: the IL-2Rα chain (CD25), HLA-DR, 
and CD38. Women using IPCs had more cervical target cells expressing CD25, which is found 
on activated and regulatory T cells (p = 0.0193, Figure 4.5A). However, there was no difference 
in the proportion of target cells expressing CD25 between IPC users and women in the follicular 
phase (Figure 4.5C), indicating that the higher proportion of CD25+ target cells in IPC users 
was driven by the underlying higher target cell frequency, and not by any direct effect of 
progestin-only contraceptives on T cell activation. IPC users also had a non-significant trend 
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towards more cervical target cells co-expressing HLADR and CD38 (Figures 4.5B and D). 
Once again, there were no differences in the activation state of target cells in the peripheral 
blood. Thus, IPC users have not only a higher frequency of cervical target cells, but also more 
activated CD25+ target cells. 
 
 Since we found that women with high exogenous progestins in the form of an injectable 
contraceptive have higher target cell frequencies, we then asked whether endogenous 
progesterone had the same effect. Only women abstaining from any contraceptive, except for 
condoms, were considered. We compared women in the follicular phase (endogenous 
progesterone ≤ 0.3 ng/mL) to those in the luteal phase (endogenous progesterone ≥ 1.2 ng/mL). 
We found a modest but significantly higher target cell frequency (p=0.0489, Figure 4.6A) and 
 
Figure 4.5 IPC use is associated with increased CD25+ activated cervical HIV target cells. 
Controlling for low endogenous progesterone level, injectable contraceptive use correlates with a 
higher proportion of activated HIV target cells (CCR5+ CD4+ T cells) amongst all live CD4+5+ cells, 
with activation defined by (a) CD25 expression, in the cervix but not the blood, and trends toward (b) 
higher HLA-DR and CD38 co-expression. However, as there is no difference in the proportion of 
CCR5+ CD4+ T cells expressing (c) CD25+ or (d) HLA-DR+ CD38+. Only cytobrushes with over 500 
live CD4+5+ cells were included in the analysis. 
 105 
more CCR5 expressing CD4+ T cells (p=0.0357, Figure 4.6B) in women in the luteal phase 
compared to those in the follicular phase. These findings support a role for both endogenous 
and exogenous progestins in modulating the frequency of cervical target cells.  
 
 Women using injectable progestin-only contraceptives also have simultaneous 
suppression of both endogenous estradiol production (Figure 4.2B). Estradiol has independent 
effects from progesterone, such as increasing the thickness of the vaginal epithelium (26, 27) 
and decreasing T cell migration in vitro (28, 29). We did not find a difference in target cell 
availability amongst women who were not using family planning and had low (<0.3 ng/mL) 
progesterone when we compared women with an estradiol concentration below 50 pg/mL to 
those with a concentration above 90 pg/mL (Figure 4.7), though there was a trend towards 
lower CCR5 expression with high estradiol. Thus, progestin level, rather than concomitant 
effects on estradiol level, appears to account for the difference in cervical target cell frequency 
in a high-progestin state. 
 
 
Figure 4.6 (A) Increased target cell frequency in the cervix and (B) increased 
CCR5 expression on cervical CD4+ T cells are associated with a naturally high 
progestin state. Only women abstaining from any contraceptive, except for 
condoms, were considered. The follicular phase was defined as an endogenous 
progesterone level less than 0.3 ng/mL, and the luteal phase was defined as an 
endogenous progesterone level greater than 1.2 ng/mL. P value refers to Mann-
Whitney test. Only cytobrushes with over 500 live CD4+5+ cells were included in the 
analysis. 
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 To understand whether a difference in concentration of soluble cytokines or chemokines 
could help explain the differences in target cell frequency at the cervix based on progestin state, 
we compared the levels of 19 cervicovaginal lavage (CVL) cytokines. There was a non-
significant trend towards higher CCL5 (RANTES) concentrations in DMPA and Nuristerate users 
(Figure 4.8). IL-10 concentrations were significantly different across groups (p=0.022, ANOVA, 
Figure 4.8) before correcting for multiple comparisons. The remaining cytokines showed no 
trend. Thus, menstrual cycle phase and IPC use do not have distinct genital cytokine signatures 
in this cohort. 
 
  
Figure 4.7 Controlling for low progesterone, there is no difference in cervical target 
cell frequency when comparing women with low vs. high estradiol concentrations, 
Only women who were not using a family planning method and cytobrushes with over 500 
live CD4+5+ cells were included in this analysis.   
 
Figure 4.8 Cervicovaginal lavage concentrations of CCL5 (RANTES) and IL-10 
among naturally cycling women in the follicular phase (n=33) or luteal phase (n=16) 
of the menstrual cycle,  or women using DMPA (n=41) or NET-EN (n=10).  
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 Finally, we asked whether there were any differences in the cervical microbiota between 
IPC users and women not using family planning. Neither linear discriminant analysis at the 
species level nor a Fisher’s exact test of cervicotype distribution revealed any significant 
bacterial differences. It is unlikely that bacterial differences are driving the increased target cell 
frequency in IPC users. 
Discussion 
In this cohort, as in several studies published previously (6-11, 30), we observed that a 
strikingly higher proportion of women who used IPCs became infected with HIV than women 
who did not use a non-condom family planning method. When we examined Nuristerate and 
DMPA separately, we found that Nuristerate users were at greater risk than those not on family 
planning, and the risk with Nuristerate was higher than with DMPA. This finding agrees with 
some (31, 32), but not all previous studies (33, 34). Due to the small number of participants in 
this sub-IPC analysis, the confidence interval was very large though still significant. Our results 
support that IPCs generally, not just DMPA, increase HIV acquisition risk. 
Behavioral and demographic confounders have traditionally obscured a definitive 
analysis of an association between IPC use and HIV acquisition risk (35). In the present study, 
participants were from a narrow age range and one residential area. This necessarily minimized 
the behavioral and demographic differences between women using IPCs and women not using 
a family planning method. Surprisingly, we still observed a few behavioral and demographic 
differences: women using IPCs were older by a year, had sexual partners who were a year 
older on average, and were having about one more sex episode per week (Table 4.1). These 
differences are consistent with trends of IPC use across South Africa (13).  
We used a Cox proportional hazard model, with HIV acquisition as the dependent 
variable, to assess each potentially confounding variable with IPC use. IPC use remained highly 
significant even when the age of the sexual partner and sexual frequency were included as 
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variables. Thus, behavioral and demographic confounders could not explain the profound 
increase in HIV acquisition risk in this cohort’s IPC-using group, so we pursued a biological 
explanation for this increased risk. 
In vitro studies have suggested that endogenous reproductive hormones and exogenous 
progestins may affect immune cell function (15, 16, 36-38). High progesterone in non-human 
primates also caused increased SIV transmission (39-41) We therefore assessed the 
immunological environment of the FGT in the context of IPC use and found that women using 
IPCs had a significantly higher HIV target cell frequency and expression of CCR5 on cervical 
CD4+ T cells (Figure 4.4). The increased expression of CCR5 on CD4+ T cells in the context of 
IPC use could be due to increased expression of CCR5 on existing CD4+ T cells, prevention of 
down-regulation of CCR5, increased trafficking of CD4+CCR5+ T cells to the FGT, increased 
migration to the cervical epithelial surface where the cells are sampled using the cytobrush, or 
proliferation of existing CD4+CCR5+ T cells in the FGT. Increased migration of CCR5+ CD4+ T 
cells to the epithelial surface would be consistent with the study by Mitchell et al., which did not 
find a difference in total CD3+CCR5+ cell frequency upon immunohistochemical 
characterization of vaginal biopsies from women on DMPA, but did not assess cellular 
localization (42). The increased frequency of activated target cells could have important 
implications for the early stages of HIV infection because activated target cells are not only 
infectable but also support large amounts of viral replication (23), facilitating viral dissemination 
from the initial local infection in the FGT (15, 25). 
Different types of progestins – DMPA, NET-EN and endogenous progesterone – may 
each have a unique influence on immune cells, although they may also act through common 
pathways because of their structural and biological similarity (15, 43). To begin characterizing 
the mechanism behind increased target cell frequency in the context of IPC use, we further 
stratified the cohort based on progestin exposure. Women in a high progestin state (naturally 
cycling and with high endogenous progesterone or using DMPA or NET-EN but with low 
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endogenous progesterone) all had increased HIV target cell frequency in the cervix compared to 
women in a low progestin state (naturally cycling with low endogenous progesterone) (Figure 
4.4 and 4.6). There was no difference among high-progestin states, suggesting that they may 
have at least overlapping immunomodulatory effects to all be associated with increased target 
cell frequency at the cervix.  
Although the use of IPCs, particularly DMPA, has been of particular interest with respect 
to increased HIV acquisition risk, the luteal phase of the menstrual cycle has also been 
described as a time of high risk of HIV acquisition (39, 44, 45). The luteal phase is characterized 
by high endogenous progesterone. By using both LMP and plasma progesterone level to define 
follicular and luteal phases, there was a small but significant increase of HIV target cell 
frequency in the luteal phase, just as in the context of IPC use (Figure 4.6). 
The level of estradiol fluctuates over the course of the menstrual cycle and is 
suppressed with IPC use (Figure 4.2B), but the cervical immune cell frequency did not differ 
based on estradiol level (Figure 4.7). This suggests that the effect of increased target cell 
frequency is primarily driven by progestin level, rather than by the low-estrogen state 
accompanying IPC use or by estradiol fluctuations during the menstrual cycle (11, 46, 47). 
Furthermore, differences in cytokine concentrations do not appear to drive the difference in HIV 
target cell frequency, because there was no difference in cytokine concentrations, in contrast to 
previous work (48). 
By analyzing the effect of IPCs on the FGT immune environment in situ, we propose a 
plausible biological mechanism for the significantly increased risk of HIV acquisition in women 
using IPCs. Although this increased risk has been previously reported epidemiologically, the 
women using IPCs in the present study have few differences in other HIV risk factors compared 
to their peers using no hormonal contraceptive. However, latent behavioral and demographic 
confounders still make any epidemiological assessment of risk difficult to interpret. Our in-depth 
assessment of the FGT immune environment under the influence of these IPCs provides a 
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powerful explanation for why women using IPCs acquire HIV at such high rates. Our 
interrogation of different progestins suggests that increased HIV acquisition risk is likely driven 
by a high progestin state, as supported by previous studies in model systems (39, 44, 45). This 
significance of this analysis is two-fold. First, our findings in naturally cycling women, comparing 
progesterone level and menstrual cycle phase, further support that these differences in cellular 
phenotype and frequency are not due to behavioral or demographic confounding. Second, if the 
target cell effect is truly mediated by both exogenous and endogenous progestins, as our data 
suggest, then increased HIV acquisition risk may impact not only women using IPCs but also 
naturally cycling women in the luteal phase. In that case, research and policy efforts should shift 
to understanding the mechanism of increased target cell availability and to developing a 
biological prophylactic to inhibit that mechanism. 
 
Materials and Methods 
Study cohort and sample collection 
HIV-negative women ages 18-23 were recruited for the Females Rising through 
Education, Support, and Health (FRESH) study, a 12-month non-randomized, closed cohort, 
prospective study conducted outside of Durban, South Africa. Participants were eligible for the 
study if they were able to understand the information and consent forms, willing to adhere to 
study requirements, willing to have HIV testing performed twice-weekly, and willing to have 
samples stored. Participants were excluded from the study if they were pregnant, anemic, or 
enrolled in any other study.  
Twice a week, participants attended classes focused on personal empowerment, job 
skills training, and HIV prevention, and had a finger prick blood draw for HIV RNA testing. A 
baseline demographic assessment was administered by a counselor in private upon enrollment. 
Participants had a pelvic exam, phlebotomy, and completed a counselor-administered HIV risk 
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questionnaire every three months. All participants received intensive HIV-prevention education 
and counseling, free condoms, and sexually transmitted infection testing. The study protocol 
was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal 
(Durban, South Africa) and the Massachusetts General Hospital Institutional Review Board 
(Protocol 2012P001812/MGH; Boston, MA). Informed consent was obtained after the nature 
and possible consequences of the study were explained.  
Procedures 
A single nurse performed all of the pelvic exams, during which a posterior fornix swab 
was used for sexually transmitted infection (STI) testing, a cervicovaginal lavage (CVL) with 5 
mL of normal sterile saline was performed using a sterile Pasteur pipette, and cellular collection 
was performed by fully inserting a cytobrush (Cytobrush Plus GT, Cooper Surgical) into the 
endocervical canal and rotating twice exactly 360°. Immediately after collection, the cytobrush 
was placed into antibiotic supplemented RPMI media with 10% FCS. The cytobrush and CVL 
were stored at 4°C for 1-3 hours during transport to the laboratory. In the laboratory, the CVL 
was centrifuged at 4°C to fractionate the cellular component from the supernatant; the 
supernatant was aliquoted and stored at -80°C. Plasma was isolated by centrifuging peripheral 
blood collected in ACD vacutainers for 15 min at 2600 rpm and aliquoting the plasma 
supernatant. Peripheral blood mononuclear cells were isolated from the remaining material 
using a standard Ficoll gradient. 
Sexually transmitted infection (STI) detection 
STIs were tested independently at Global Labs (Durban, South Africa) from a posterior 
fornix swab. Neisseria gonorrhoea and Chlamydia trachomatis were tested using the GeneXpert 
CT/NG assay (Cepheid). Trichomonas vaginalis, HSV-1, and HSV-2 were tested by real-time 
PCR on a LightCycler (Roche). All positive results for Trichomonas, HSV-1, and HSV-2 were 
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retested, and inconsistent results were sent to an outside lab for a third confirmatory test. 
Participants with positive STI results were referred for treatment at an outside facility. 
Progesterone and estradiol measurement 
Plasma progesterone and estradiol levels were measured by the Massachusetts 
General Hospital Clinical Laboratory Research Core (MGH CLR) using Chemiluminescent 
Microparticle Immunoassays (CMIA) (Abbott Laboratories). Progesterone values below the limit 
of detection (0.1ng/mL), values were read as half the minimal limit of detection (i.e. 0.05ng/mL). 
Estradiol values below the limit of detection (10pg/mL), values were read as half the minimal 
limit of detection (i.e. 5pg/mL). Progesterone cutoffs for follicular and luteal phases were 
determined based on the CMIA package insert. 
Immunophenotyping of cervical cytobrush samples 
Cervical cells were dislodged from the cytobrush and washed. Cell surface staining was 
performed using monoclonal antibodies to the following human proteins: CD4+5 (HI30), CD3 
(UCHT1), CD8+ (SK1), HLA-DR (G46-6), CD38 (HIT2), CD25 (2A3), CCR5 (2D7), CD11c (B-
ly6), CD14 (M5E2), CD19 (HIB19) from BD Biosciences; and CD4+ (S3.5) from Life 
Technologies. All antibodies were titrated before use. Viable cells were identified by a 
LIVE/DEAD violet stain (Life Technologies). Rainbow beads (Spherotech) were used to ensure 
comparable fluorescence measurements between experiments. Cells were passed through a 
70µm filter prior to analysis on the FACS Aria III (BD Biosciences). Fluorescence minus one 
controls for CD38, HLA-DR, CD25, and CCR5 were performed on peripheral blood 
mononuclear cells in each experiment. Cells were sorted directly into TRIzol (Life 
Technologies), vortexed vigorously, and stored at -80°C. Data were processed using FlowJo 
software (Treestar). CD4+ T cells were gated by: FSC vs. SSC, singlets, live CD19-, CD4+5+, 
CD3+, CD4+ CD8-. CD8+ T cells were gated by: FSC vs. SSC, singlets, live CD19-, CD4+5+, 
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CD3+, CD4+- CD8+ . Antigen presenting cells were gated by: FSC vs. SSC, singlets, live 
CD19-, CD4+5+, HLA-DR+ CD3-, and CD11c+ or CD14+.  
Cytokine measurements in CVLs 
Cytokines were measured using a human cytokine/chemokine multiplexed bead assay 
(Millipore) for IL-1β, IL-2, IL-4, IL-6 IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, IL-1α, IL-1RA, CXCL10 
(IP-10), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), sCD40L, G-CSF, GM-CSF, FTL-3L, 
and IFN-α2. The multiplexed bead assay was performed according to the manufacturer’s 
protocol. A quality control was included with every plate to ensure reproducibility. Cytokine 
measurements below the limit of detection were assigned a value of half of the minimum 
detectable concentration for that cytokine. 
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 Chapter 5: Conclusions and Broader Impacts  
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Summary and discussion of main findings 
By integrating metagenomic, immunologic, transcriptional, and behavioral datasets from 
a population of young South African women, we demonstrate that endogenous alterations in 
cervicovaginal bacteria and exogenous injectable progestin-only contraceptives induce distinct 
forms of genital inflammation in vivo.  
Unlike most women in the U.S., a minority of South African women in FRESH had 
Lactobacillus dominant genital communities, with a particularly low prevalence of L. crispatus. In 
this small subset of women, L. crispatus maintains its immunologically discreet dominance 
through a variety of mechanisms. By feasting on the glycogen stored in the cervicovaginal 
epithelium, L. crispatus produces copious lactic acid under anaerobic conditions (1) that 
acidifies the vagina to a pH as low as 2.8 (2). The growth of other organisms, like Gardnerella 
vaginalis and Candida albicans, is inhibited at this pH (3, 4). The low pH may even be protective 
against HIV by neutralizing cell-free HIV virions (5) and reducing the viability of infected cells 
carrying HIV (6). But in the context of sexual HIV transmission, the alkaline seminal pH buffers 
the acidic vaginal pH, thereby reducing lactic acid’s potential protective effects against HIV. At 
steady state L. crispatus protects its niche in other ways, such as producing bacteriocins and 
hydrogen peroxide (7), and physically displacing other bacteria by adhering to the epithelial 
surface (8). Thus, L. crispatus is well-adapted to inhabiting the glycogen-rich niche of the human 
lower genital tract and has numerous mechanisms to protect its niche. 
  We demonstrate here that the inflammatory state of a L. crispatus-dominant community 
is low. Co-culture of vaginal epithelial cells with L. crispatus induces no additional cytokine 
secretion than from media alone (Figure 3.3). In cervicovaginal lavages from women with L. 
crispatus dominance, IL-1α and IL-1β concentrations are very low, and TNF-α and IFN-γ are 
undetectable (Figure 2.6). The cervical antigen presenting cells are not activated (Figure 3.2). 
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and the CD4+ T cell frequency is low (Figure 4.6). Overall, L. crispatus bacterial colonization is 
associated with a low inflammatory state and likely low HIV acquisition risk. 
In contrast, the majority of women in our cohort either had a community composed of 
Gardnerella and Atopobium vaginae (CT3) or Prevotella, Shuttleworthia, Sneathia, Gardnerella, 
Mobiluncus, and Megasphaera (CT4) (Figure 2.1). CT4 is a much richer cervicovaginal 
community, with a higher overall bacterial count (9) that contributes to a scarcity of glycogen for 
fermentation, causing bacteria to turn to glycerol as an alternative energy source (10). The pH 
rises above 5.5 (11) from the lack of lactic acid fermenting bacteria and excess tyramine (12). 
Overall, our shotgun sequencing (Figure A2.2) and the work of others demonstrates that 
polymicrobial CT4 communities produce a dramatic shift in the microbial functions present in the 
genital tract from that of an L. crispatus-dominant community. 
 We found that CT4 bacteria are associated with high concentrations of IL-1α, IL-1β, 
TNF-α, IFN-γ, IL-10, and IL-8 in the genital tract (Figure 2.6). In this thesis, we also elucidated 
facets of the immunological response underlying this cytokine signal. Vaginal epithelial cells 
performing their barrier function produce IL-1α, IL-1β, and IL-8 in response to CT4 community 
members such as Prevotella amnii, Mobiluncus mulieris, Sneathia sanguinigens and S. amnii, 
(Table 3.2). Disruption of the mucus barrier by sialidases made by bacteria like Prevotella and 
Gardnerella (10) may accentuate this response due to closer contact between vaginal epithelial 
cells and bacteria. The mechanism of epithelial cell IL-1β secretion may be from sensing 
bacterial dsRNA through TLR3 or RIG-I, leading to caspase-1 activation and cleavage of pro-IL-
1β into its active form (Figures 3.4-3.6). The released active IL-1β acts on nearby stromal cells, 
such as endothelial cells and fibroblasts. The endothelial response to IL-1β includes increased 
adhesion and recruitment of neutrophils and monocytes (13), and cervical fibroblasts respond 
by increasing collagen and glycosaminoglycan synthesis (14). Active IL-1β can also have 
effects on local immune cells, like antigen presenting cells. The cervical antigen presenting cells 
that we focused on were macrophages and dendritic cells, due to exclusion of CD19+ B cells in 
 121 
the FACS sorting panel (Figure 3.1C). IL-1β was predicted to be an upstream regulator of the 
CT4-associated APC transcriptional signature, and IL1B was also one of the genes upregulated 
in CT4 APCs (Figure 3.2).  
 CT4 APCs also had a profound resemblance to LPS-treated monocytes and dendritic 
cells when compared to CT1/2 APCs (Figure 3.2). This is not surprising since we found that 
CT4 bacteria produced significantly more LPS than Gram-positive Lactobacilli (Table A2.2). As 
cervical APCs reside underneath the epithelium or in the lamina propria (Figure 3.1A,B), the 
exact mechanism by which APCs contact bacterial LPS is unclear. APCs may extend dendritic 
processes into the lumen, or there may be damage to the epithelial barrier that allows luminal 
bacteria or their bacterial products to directly access the subepithelial APCs. This damage could 
come from direct bacterial invasion (15) or from disruption of the tight junctions comprising the 
epithelial barrier by TNF-α and IFN-γ, which were clearly in the cervicovaginal secretions 
(Figure 2.6) (16, 17). 
 Regardless of the route of LPS exposure, CT4 APCs appeared activated, with higher 
CD80, ICAM-1, and MHC class II gene expression levels (Figure 3.2). CT4 APCs also 
upregulated inflammatory cytokine expression such as IL1A, TNF, and IL6, in addition to the 
aforementioned IL1B, and chemokines such as CCL4, CXCL9, and CCL8. Activated dendritic 
cells within the APC pool may be carrying antigen to the draining lymph node and inducing a T 
cell response specific to these bacteria. This process may have driven the increased cervical 
CD4+ T cell frequency seen in Figure 2.8, but further experiments are needed to demonstrate 
this connection. Local T cells, as well as local natural killer cells, produce IFN-γ and may have 
contributed to the higher IFN-γ concentration seen in CT4 CVLs (Figure 2.6F). IFN-γ was also 
predicted to be an upstream regulator of the CT4 APCs. 
 Finally, the increased CVL IL-10 concentration (Figure 2.6G) in conjunction with the 
APC transcriptional signature (Figure 3.2A) suggested that inflammatory monocytes may be 
attempting to resolve the mucosal inflammation. ARG1, PTGS2, IL10, IDO1, CCL4, IL6, IL1A, 
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and IL1B were upregulated both in our CT4 APCs and FACS-sorted mouse intestinal 
inflammatory monocytes from a T. gondii infection mouse model (18). Additional genes 
upregulated in CT4 APCs, such as THBS1, NEK7, OSM, and PLEK, are also involved in wound 
healing processes. Interestingly, the T. gondii mouse model demonstrated that inflammatory 
monocytes inhibited neutrophil activation and limited tissue damage during pathogen-induced 
inflammation (18). It has been previously noted that bacterial vaginosis surprisingly does not 
necessarily have a neutrophilic infiltrate (19) despite elevated IL-8 concentrations (Figure 2.6H), 
and it is tempting to speculate a role for inflammatory monocytes in this observation.  
Overall, the characteristics of the complex inflammatory response to CT4 bacteria is 
becoming increasingly clear, as is the link to HIV risk. We found a trend towards increased HIV 
acquisition risk among women with CT4 bacterial communities compared to those with 
Lactobacillus crispatus dominance, with a hazard ratio of 3.5. We also found particular bacterial 
taxa robustly enriched in women who became infected, including several Prevotella, Sneathia, 
Peptoniphilus, and L. iners taxa. This is supported by prior observations that pro-inflammatory 
cytokines in CVLs are associated with an over 3-fold increased risk of HIV acquisition in women 
(20) and that HIV-1 exposed women who remain seronegative have lower levels of genital 
IFN-γ, IL-1α, and CXCL10 (21).  
Of the several possible mechanistic links between CT4 bacteria and HIV acquisition, the 
increase in activated HIV infectable CD4+ T cells in the cervix of women with high pro-
inflammatory cytokines provides a potential cellular route. Additionally, damage to the columnar 
epithelial barrier of the endocervix by cytokine-mediated disruption of tight junctions may enable 
both bacterial and viral translocation (16, 17). TNF-α and IL-1β also stimulate HIV replication 
through NF-κB activation (22), especially in HIV-1 clade C viral infections that are the most 
prominent subtype in sub-Saharan Africa (23). Thus, our study identifies several ways in which 
the predominant cervicovaginal communities found in our cohort of South African women impact 
genital inflammation and thereby likely modulate HIV acquisition risk. 
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Independent of cervicovaginal bacteria, we found that women using an IPC were five 
times more likely to acquire HIV than women not using a family planning method. Among IPC 
users, women using Nuristerate were infected at higher rates than those using Depo-provera. 
Though IPC users were more likely to have slightly older sexual partners and have one more 
sexual act per week, IPC use remained significantly associated with HIV acquisition when these 
factors were incorporated into a Cox proportional hazards model. In search of a biological 
mechanism behind this increased risk, we assessed CD4+ T cell frequency and phenotype in 
the cervix and peripheral blood. We found that IPC users on average had a higher frequency of 
CCR5+ CD4+ T cells in the cervix due to higher CCR5 expression levels on the cell surface 
(Figure 4.4); this could from an upregulation of CCR5 expression on CD4+ T cells, prevention 
of CCR5 downregulation, or preferential localization of CCR5+ CD4+ T cells at the epithelial 
surface that is sampled with a cytobrush. The observed increase of CD25 expression on target 
cells in IPC users (Figure 4.5) may indicate higher cellular activation or an increase in Tregs, 
which have been shown to be induced by progesterone (24). There was a non-significant trend 
towards more cervical CD38+ HLA-DR+ target cells with IPC use, suggesting that activation is 
at least a component of the CD25 signal. Conversely, we did not see differences in any genital 
cytokine concentrations in IPC users compared to women not using family planning in the 
follicular or luteal phase, nor did we see differences in the genital bacterial microbiota (Figure 
4.8 and A3.1). While the mechanism behind the increased target cell frequency in cervical 
tissue of IPC users is still unclear, these data support the hypothesis that IPC use increases HIV 
acquisition risk. The IPC mechanism is largely distinct from that of diverse bacterial 
communities, though there may be common path with increased target cell frequency. 
 For the first time in humans, we were also able to assess the dynamics of HIV 
dissemination in acute infection. We found that the peak CVL viral load was about a week 
before the peak plasma viral load (Figure 2.10C) and the viral load was detectable earlier in the 
CVL than the plasma, supporting the hypothesis that the virus first replicates within the genital 
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mucosal tissue before spreading systemically. Although anecdotal, two women with L. crispatus 
and L. iners vaginal bacterial communities had nearly undetectable CVL viral loads throughout 
acute infection despite having millions of viral copies per mL of plasma (Figure 2.10B). These 
two women also had low levels of pro-inflammatory cytokine levels within the bacterial 
signature, suggesting that HIV does not replicate effectively in the genital tract when 
inflammation is not present. We also determined a viral cytokine signature that was generally 
distinct from the CT4 bacterial cytokine signature that we had defined previously. Genital levels 
of CXCL10, CCL5, sCD40L, GM-CSF, CXCL8, and TNF-α were significantly higher at peak viral 
load than before infection.  
 Finally, because the gut bacteriome is significantly altered in chronic HIV infection (25-
27), we thought that the vaginal bacteriome would also shift in acute HIV infection when the 
genital viral load reached 10,000 to 1,000,0000 copies per mL and there was a massive 
depletion of CD4+ T cells. Though our sample size of 15 was small, we did not see significant 
changes in bacterial species abundance between acute and chronic infection (Figure 2.12), nor 
in overall community stability compared to HIV negative women (Figure 2.14). The only phylum 
that was significantly different in chronic versus acute infection was an unknown Rickettsiales 
family member, which was present at greater than 10% abundance in several women at the first 
week post-infection but decreased in abundance at chronic infection (Figure 2.13). We also saw 
a significant reduction in HIV-positive women with CT1 bacterial communities compared to HIV-
negative women (Figure 2.14), as previously reported (28), but we believe this is likely a 
consequence of fewer women with CT1 communities becoming infected in the first place. 
Overall, the surprisingly stability of cervicovaginal bacterial communities in HIV infection 
suggests that these bacteria do not rely on CD4+ T cells for survival and are not significantly 
affected by changes in the cytokine milieu. 
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Strengths and weaknesses of approaches taken 
Focusing on the FRESH cohort of young, sexually active women 
 Strengths: The FRESH study provided a unique opportunity to focus on understanding 
the causes of genital inflammation in a demographic that is particularly vulnerable to HIV 
infection: 18 to 23 year-old women in an area with high HIV prevalence. This is the target 
demographic for novel pre-exposure prophylaxis methods that are female controlled and HIV 
vaccines that are in development. Since microbicides like intravaginal tenofovir gel have been 
shown to fail in women with high inflammation, we hope that understanding the causes of 
inflammation in the same group that will be using these interventions will inform and improve 
their efficacy.  
 FRESH also offered several logistical advantages. At the start of the study we 
established the mucosal sampling methods to collect the appropriate specimens to answer our 
scientific questions in a sterile and reliable manner. We trained the dedicated nurse who 
performed all the pelvic exams herself, ensuring consistency across samples. We also trained 
the lab staff at the Harvard Pathogenesis Program at the University of KwaZulu-Atal School of 
Medicine to preserve cell viability and maximize yields when isolating cells from the cervical 
cytobrush and peripheral blood samples.  
We performed the experiments described in this thesis while the study was on-going, 
which enabled us to perform on-going quality control checks and perform experiments on fresh 
samples. For example, we were able to perform cellular phenotyping and sorting at the 
KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) within hours of sample 
collection, thereby avoiding a freeze-thaw cycle and maintaining viability of the fragile cervical 
cells. Unlike studies that utilize archived samples from completed clinical trials, we were able to 
perform cervicovaginal lavage cytokine measurements within approximately six months of their 
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collection, avoiding degradation of cytokines during storage. Thus, we are very confident in the 
quality of the samples that we utilized. 
 The participants’ twice-weekly visits to the study site over the course of a year also 
afforded numerous advantages. The participants received intensive counseling about sexual 
health, HIV, and the goals of the mucosal sampling, and received the benefit of unprecedented 
access to medical care and three-monthly sexually transmitted infection testing. As a result of 
this education and the concurrent classes focusing on empowerment and employment, the 
participants were very invested in the study. We believe this translated to honesty in the 
behavioral questionnaires, as we could validate their self-reports of contraceptive usage by 
measuring plasma drug levels, last menstrual period with plasma progesterone and estradiol 
measurements, and last reported sexual activity by measuring prostate specific antigen in 
CVLs. The high-frequency HIV viral load testing afforded a unique opportunity to identify women 
within days of HIV infection. The principal investigators were also able to obtain IRB approval to 
begin very early anti-retroviral treatment, which is on-going. 
 Weaknesses: One weakness of the study was the lack of involvement of the male sexual 
partners. It would have been very informative to collect information about the sexual partners’ 
penile microbiome and genital inflammation level. Additionally, our participants were counseled 
to seek antibiotic treatment for themselves upon receiving a positive STI test results and they 
were told to disclose to their sexual partners, but we do not know how often this happened. As a 
result, our participants may have been re-infected with STIs from their untreated partners. 
 Another weakness was the small size of the study, with an original enrollment goal of 
300 women. The intensive nature of the FRESH educational curriculum limited its size. 
 Alternative approaches: We could have performed higher frequency mucosal sampling 
with biopsies in women enrolled from Boston, MA. However, in hindsight we were unlikely to 
have seen the inflammatory signal of CT4 bacteria as the proportion of women in U.S. with this 
community type is small. We could have also utilized archived samples from a larger, completed 
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South African clinical study, but we would have had to rely on their pre-determined mucosal 
sampling conditions and behavioral questionnaires. We would also not have been able to 
perform meaningful cellular analyses. 
Characterizing inflammatory properties of bacteria in women 
Strengths: Determining associations between genital bacteria and pro-inflammatory 
cytokines in women ensured the biological relevance of our findings. It allowed us to determine 
and focus on the bacterial species that are prevalent in the target demographic for preventative 
HIV interventions. 
 Weaknesses: In our observational study in humans, we cannot demonstrate the causal 
link between particular genital bacterial communities and HIV acquisition. We are limited to 
showing strong associations in both cross-sectional and longitudinal analyses that argue for 
causation. Additionally, mechanistic studies are very difficult in humans, without the 
unprecedented control over experimental conditions afforded by mouse models. 
 Alternative approaches: NOD scid gamma (NSG) mice reconstituted with a human 
immune system are the only the model system for HIV infection, and non-human primates 
infected with simian immunodeficiency virus (SIV) or chimeric HIV-SIV viruses (SHIV) offer 
another very relevant model. The vaginal microbiome of non-human primates vary by species, 
but are generally not Lactobacillus dominant and tend to contain some CT4 bacteria like 
Prevotella and Sneathia (29). Both conventional and gnotobiotic mice have proven to be useful 
in dissecting microbe-host interactions in the gut and skin (30-34). Mouse models for the vaginal 
microbiome currently do not exist, with the exception of a monocolonization model with 
Gardnerella vaginalis (35). Only one published study has determined the natural vaginal 
bacteriome of mice and it is more similar to human skin, with colonization mostly by 
Acinetobacter or Streptococcus (36). We are currently exploring the possibility of using the 
humanized mouse model, as discussed in the next section on “Future Studies”.  
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Bacterial characterization using 16S V4 sequencing and shotgun sequencing from 
cervical swabs 
Strengths: The 16S rRNA gene contains nine hypervariable (V) regions, and several 
primer sets have been designed to amplify different sets of V regions. There is no consensus 
regarding the optimal V region to sequence for vaginal microbiome studies. While the Human 
Microbiome Project recommends using the 27F and 338R primer set to amplify the V1-V2 
region, this primer set fails to amplify Bifidobacteriaceae in general and completely 
underestimates the abundance of G. vaginalis (37). Rob Knight’s group developed a robust set 
of V4 primers using 515F and Golay-barcoded 806R that have been widely used in a variety of 
settings through the Earth Microbiome Project (38). We decided to use these V4 primers for our 
study and they effectively amplified Gardnerella and enabled us to multiplex over 100 samples 
on a single MiSeq run. 
 Weaknesses: Several species within the Lactobacillus genera do not have much unique 
variation in the V4 region. Thus, we had to use the supplementary approaches of shotgun 
sequencing and oligotyping to distinguish L. crispatus from other Lactobacilli. 
 Alternative approaches: David Fredricks’ group has investigated the vaginal microbiome 
using 338F and 806R (39). This primer pair seems to both amplify Gardnerella and distinguish 
between most Lactobacillus species. 
Pro-inflammatory cytokine measurements from cervicovaginal lavages (CVLs) using a 
multiplexed bead assay 
Strengths: We collected cervicovaginal secretions using a 5 mL saline lavage. After 
pelleting cellular debris, approximately 4 mL of lavage supernatant remained for future assays. 
Using regular and high-sensitivity Luminex multiplexed bead assay kits, we were able to 
measure 19 cytokines in duplicate using only 200 µl of CVL, allowing us to conserve precious 
material. Luminex kits include internal quality controls and have low inter-plate variability, 
allowing direct comparisons of samples collected throughout the duration of a study and 
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assayed on different days. Luminex kits have also been used by many other groups studying 
CVL cytokine concentrations, including our collaborators at CAPRISA (40), which simplifies 
inter-study comparisons.  
 Weaknesses: CVLs necessarily dilute cervicovaginal secretions by 5 to 10-fold. While 
every effort is made to ensure consistency across sampling, there is inevitably some variation 
that adds noise to the cytokine measurements. When we compared CVL cytokine 
measurements collected from the same participant over time, we were pleased to see that intra-
individual variability was far less than the inter-individual variability. Both the CVL dilution factor 
and Luminex assay sensitivity limit contributed to several pro-inflammatory cytokine 
measurements falling below the minimum detection concentration in CT1 and CT2 women. A 
more sensitive assay would likely have accentuated the cytokine differences between CT1/2 
and CT3/4. 
 Alternative approaches: Other groups have collected cervicovaginal secretions using an 
absorbent swab or Weck-Cel sponge, and cervical secretions using a SoftCup diaphragm that 
fits over the cervix. While these methods collect secretions without dilution, they suffer from 
difficulty with retrieving cytokines from the swab, sponge, or mucus-rich secretion, and have 
lower overall protein recovery levels than CVLs (41). An alternative to Luminex would be to use 
a biomarker platform based on electrochemiluminescent technology (e.g. Meso Scale 
Discovery, MSD), which has a lower limit of detection that is 5-10 times lower than Luminex’s for 
most cytokines, and also has a lower coefficient of variance. Unfortunately, it also costs about 
three times more than Luminex and the MSD instruments are not widely available. 
Cellular phenotyping from cervical cytobrushes 
Strengths: Cervical cytobrushes are a clinically approved and relatively non-invasive 
form of cellular collection because of their use in Pap smears. Cytobrushes do not require 
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anesthetics and do not cause bleeding or trauma. The brush primarily samples the superficial 
surface of the endocervical canal. 
 Weaknesses: There is wide variation in the number of cells collected using a cytobrush. 
Some of this variation arises from the mucus contained within the cervical canal, which can 
adhere to the brush and make it difficult to retrieve single cells. Also, the location of the cervical 
transformation zone varies amongst women, and whether it is sampled by the cytobrush can 
affect cell retrieval, as the transformation zone contains a high concentration of leukocytes (42). 
Another weakness is that the cervical cytobrush does not provide information about vaginal 
immune cells.  
 Alternative approaches: In this study, we could have also collected a vaginal cytobrush, 
which is far less common and would presumably mostly contain superficial vaginal epithelial 
cells. Ectocervical and vaginal biopsies provide a high cellular yield and we commonly use them 
in our Boston-based studies, but it would not be ethical to perform biopsies in the FRESH 
participants due to concerns of increased acquisition risk from epithelial disruption and post-
biopsy inflammation. 
Validation of pro-inflammatory properties of individual bacterial species using a vaginal 
epithelial cell co-culture model 
Strengths: This reduced system with immortalized human vaginal epithelial cells and 
single bacterial species enables one to quickly and reproducibly screen for pro-inflammatory 
cytokine secretion (43). Epithelial cells comprise the majority of the cervicovaginal mucosal 
surface and directly contact bacteria, making their bacterial responses particularly relevant. 
Additionally, epithelial cells are likely a major contributor to the cervicovaginal secretions 
collected with a CVL.  
 Weaknesses: We tested vaginal bacterial isolates from the U.S. and Sweden, assuming 
they would be representative of the strains we found in South Africa. We have since started 
collecting additional cervicovaginal swabs from the FRESH study in a manner that preserves 
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bacterial viability for future bacterial cultivation. This in vitro system is also devoid of mucus, 
which may spatially separate bacteria from epithelial cells in vivo. 
 Alternative approaches: An alternative to single epithelial cell layers are commercially 
available 3-D VEC-100 multi-lamellar cultures of vaginal-ectocervical cells, or VLC-100 tissues 
which also contain dendritic cells. A group at Baylor University has directly placed freshly-
collected vaginal swabs into PBS and applied freeze-thawed bacteria from those swabs to the 
apical surface of VEC-100 tissue to measure cytokine secretion (44). In their paper, they say 
they preserved the original distribution of bacterial species after freeze-thaw, but this claim is 
based on PCR from bacterial DNA, which can come from both viable and dead bacteria. Using 
this method, it is unclear whether host factors from the original swabs, such as pro-inflammatory 
cytokines, are also preserved and transferred to the VEC-100 tissue. It is worth investigating 
this approach in future studies. 
RNASeq analysis of sorted cytobrush and peripheral blood samples 
Strengths: Despite numerous technical and logistical challenges, we were able to 
perform paired cytobrush cell and PBMC sorting directly into TriZOL, followed by RNA 
extraction and digital RNAseq using the SCRB-Seq method. We optimized the phenol-
chloroform-IAA (PCI) RNA extraction method to successful isolate RNA from as few as 20 cells 
sorted into TriZOL. Unlike most column-based RNA extraction methods, PCI extraction 
preserved microRNAs and long non-coding RNAs. SCRB-seq also enabled us to quickly and 
relatively inexpensively obtain digital gene expression from low RNA inputs. 
 Weaknesses: PCI-based RNA extraction is extremely laborious and prone to human 
error, especially when extracting from small cell numbers. In addition, SCRB-Seq provides gene 
counts but not isoform information, and the overall read depth using SCRB-Seq was less than 
we anticipated, with approximately 100,000 reads per sample. This may have hindered our 
ability to detect genes with low expression levels in the APCs. While we also performed SCRB-
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Seq on CCR5+ CD4+ T cells, CCR5- CD4+ T cells, and CD8+ T cells in addition to APCs, we 
were not able to perform deep enough sequencing to extract meaningful information. 
 Alternative approaches: The SMART-Seq2 method has now been developed to perform 
full-length transcriptome sequencing from single cells (45) and bulk populations. 
Probing the mechanism of IL-1β production from epithelial cells using human 
immortalized cell lines 
Strengths: Since caspases are activated during apoptotic cell death and pro-IL-1β can 
be released from dying cells, it is critical to perform these experiments in a setting with good cell 
viability. Due to the fragility of epithelial cells ex vivo, cervical tissue explants are not a viable 
model due to variable cell death. However, immortalized human epithelial cells are robust and 
retain many features of primary epithelial cells. Additionally, the caspase-1 FLICA probe 
combined with propidium iodide allows one to easily exclude necrotic cells by flow cytometry.  
Weaknesses: IL-1β ELISAs suffer from the problem of not discriminating between pro-IL-
1β and active IL-1β. Additionally, in the study described in this thesis, we focused on a model of 
Toll-like receptor agonist priming to upregulate NLRP3 followed by activation with ATP, but 
there are a variety of inflammasomes aside from NLRP3 that are triggered by danger signals 
other than ATP. 
 Alternative approaches: Western blots allow one to distinguish between 31 kDa pro-IL-
1β and 17 kDa active IL-1β. Utilizing a caspase-1 inhibitor like VX-765 in conjunction with 
poly(I:C) and ATP stimulation would have more convincingly shown that inflammasome 
activation specifically was important for IL-1β release. We could have also used a joint TLR-
RLR inhibitor called BX-795 to demonstrate the necessity of poly(I:C) signaling through either of 
those receptors. Finally, we could have also use siRNAs to knock-down TLR3, RIG-I, and 
NLRP3 to determine which receptor was most critical for caspase-1 activation and IL-1β 
secretion in response to poly(I:C) (46, 47). 
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In vivo approach to determining the influence of IPCs on HIV target cells 
Strengths: Examining the effects of IPCs in women obviously increases the relevance of 
the findings. This is the first study to our knowledge to demonstrate both increased HIV 
acquisition risk and cervical target cell frequency with IPC use. Using a mouse animal model 
would suffer from many limitations due to differences in natural hormone cycles (mice have a 4-
5 day menstrual cycle) and anatomic structures (mice have a bicornuate uterus). Some non-
human primates, like pigtail macaques, have 30-day menstrual cycles, but despite that similarity 
there are clearly differences in physiologic responses, such as the profound vaginal thinning 
effect high-dose progesterone observed in macaques (48, 49) but not humans (50).  
 Weaknesses: There is high biological variation in cervical target cell frequency in 
women, due to differences in time since last IPC injection, timing in the hormonal cycle, active 
and latent STIs, cervicovaginal bacteria, and the presence of cervical ectopy, among other 
reasons. Thus, seeing a signal amongst this variation requires large sample sizes. Also, as 
previously discussed, cervical cytobrushes only capture information regarding the cervical 
immune environment, and it would have been informative to acquire data on vaginal effects. 
 Alternative approaches: Miller et al. performed a well-designed study in Seattle, 
Washington that enrolled women who wished to begin using DMPA (51). The participants 
received a vaginal biopsy before receiving DMPA and at every subsequent 3-monthly visit when 
they came for their DMPA injection. Mitchell et al. assessed T cell frequency in the vaginal 
biopsies collected from that study using immunofluorescent staining (50). While it was 
convenient for the participants to get their DMPA dose at the same visit as the vaginal biopsy, it 
may have abrogated their signal because DMPA reaches peak levels about a week after 
injection, and plasma levels progressively decline thereafter (52). An improvement on this study 
would be to perform the vaginal biopsies about a month after each DMPA dose. 
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Future studies 
Analyzing cellular transcriptional networks 
 We plan to extend the antigen presenting cell transcriptional analysis presented in this 
thesis to also include sorted cytobrush cell populations of epithelial cells, neutrophils, CD4+ T 
cells, and CD8+ T cells. We anticipate that a transcriptional network analysis of both innate and 
adaptive immune cells collected at the same time from the same person whose bacterial 
microbiome has already been determined will provide an in vivo snapshot of the genital immune 
response to bacteria. We have already sorted these cell populations and will use the SMART-
Seq2 RNAseq method to achieve a higher read depth (at least 5 million reads per sample) than 
what we previously acquired with SCRB-Seq. We will also need to develop new analysis tools to 
determine gene expression changes amongst different cell types. We hope that this 
comprehensive characterization will also provide new insights into mucosal immunology. 
Developing a mouse model to study host-bacterial interactions in the FGT 
 The utility of model organisms for understanding host-microbiota interactions cannot be 
understated (reviewed in (53)). While animal models have proven very useful for studying 
sexually transmitted infections like HSV-2 (54) and chlamydia (55), a robust small animal model 
to study host-bacterial interactions in the genital tract does not yet exist. We believe the results 
described in this thesis will provide a metric for evaluating potential models of investigating the 
role of genital microbiota in genital inflammation. Specifically, a valuable model would show a 
minimal inflammatory response to Lactobacillus crispatus and a pro-inflammatory response 
consisting of at least IL-1α, IL-1β, and TNF-α secretion in response to Prevotella spp. Aside 
from the bicornuate uterus, the mouse lower reproductive tract is anatomically similar to the 
human’s, with a vagina covered by a stratified squamous epithelium, posterior fornix, and single 
cervix that contains a transformation zone (Figure 5.1), making the mouse an attractive 
potential model. 
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Figure 5.1. Anatomy and histology of the mouse lower reproductive tract. (A) The stratified 
squamous epithelium of the mouse vaginal wall in estrus. Adapted from the Atlas of Laboratory 
Mouse Histology (56). (B) Schematic of the mouse cervix (C), also showing vagina (V) and two 
uterine horns (H). Adapted from Leppi et al. (57) (C) The mouse transformation zone, with an 
arrow pointing to the transition between the squamous epithelium on the left and columnal 
epithelium on the right. Adapted from Brake et al. (58).  
 
We performed a proof-of-concept experiment with Dr. Raina Fichorova using gnotobiotic 
mice and found that seven days after intravaginal inoculation, mice treat with P. bivia had higher 
vaginal IL-1β and TNF-α concentrations as well as a vaginal CD4+ T cell infiltrate compared to 
mice treated with L. crispatus, which had comparable pro-inflammatory cytokine levels and 
CD4+ T cell frequencies to the PBS treated controls. It will be important to determine that CT4 
bacterial species like Prevotella spp. are not invading the mucosa of these mice, which could 
explain the vigorous inflammatory response, and whether conventional specific-pathogen-free 
(SPF) mice have similar responses. Using SPF mice would provide far more opportunities to 
explore the mechanism behind the inflammatory response, due to the wide variety of mutants 
available. Alternatively, establishing the model in NOD scid gamma (NSG) mice reconstituted 
with a human immune system via a bone marrow, fetal liver, and fetal thymus transplant would 
provide an opportunity to challenge the mice with HIV after intravaginal bacterial inoculation 
(59).  
Filling in the metagenomic gaps by examining the virome and mycome 
 The microbial foci of this thesis were bacteria and HIV, but the virome and mycome are 
increasingly being appreciated as important contributors to human health (60, 61). The human 
virome is primarily comprised of four types of viruses: viruses that infect human cells, viruses 
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that infect parasites that live within us, bacteriophages that infect bacteria that live within us, and 
genetic elements from viruses that have integrated into the human genome, such as prophages 
and endogenous retroviruses (60). In collaboration with Dr. Skip Virgin’s lab at Washington 
University in St. Louis, we are characterizing the human vaginal virome and fungome in the 
FRESH cohort, determining their contribution to genital inflammation, and examining their 
potential bacterial modulatory effects. From our preliminary data and the work of others (62, 63), 
we expect the vaginal mycome to contain at least Candida albicans, we expect the vaginal 
virome to contain at least bacteriophages, herpesviridae, anelloviridae, and Trichomonas 
vaginalis virus. Bacteriophages may play a particularly important role in our cohort, as shifts in 
bacterial communities may actually be driven by bacteriophage changes (64).  It is temping to 
speculate that bacteriophages induce the vaginal microbial changes that we saw in our 
longitudinal analyses, by a mechanism similar to Pavlova et al.’s discovery of vaginal 
bacteriophages that preferentially lyse Lactobacilli (65).  
Extending the observations of IPC effects from humans 
  Finally, we propose to use a human cervical explant model to directly test the relative 
effects of progesterone, medroxyprogesterone acetate, norethisterone, and estrogen. We have 
a protocol in place to receive excess surgical tissue from Massachusetts General Hospital within 
hours of collection with associated clinical metadata such as the patient’s age and prior 
hormonal therapy. Blocks of cervical tissue oriented with the apical side facing up and edges 
sealed with agarose can be cultured for at least week (66) with hormones, and then either 
challenged with HIV, digested and phenotyped by flow cytometry to assess CCR5 expression 
levels, homogenized to assess RNA expression levels, or formalin fixed and analyzed by 
immunohistochemistry to assess T cell localization. While cervical explants have their caveats 
(67), we believe this approach will enable us to validate our in vivo findings.  
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Figure A1.1.  Genital cytokine correlations. (A) Correlations between cervicovaginal lavage 
(CVL) cytokine concentrations. Spearman’s rho correlation coefficients between CVL cytokines 
(using log10 normalized concentrations). Only correlations with p<0.001 are displayed. (B-D) 
Genital cytokine levels in women with or without at least one positive STI PCR result (C. 
trachomatis, N. gonorrhoea, T. vaginalis, HSV-1, or HSV-2) (B), or positive only for C. 
trachomatis versus negative for all STIs (C), or positive only for N. gonorrhoea versus negative 
for all STIs (D). Data shown as median with interquartile range. P values determined by a two-
tailed Mann-Whitney test, n=146. 
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Figure A1.2 Plasma cytokine levels amongst women with the highest or lowest levels of genital 
pro-inflammatory cytokines (n=16). Dashed lines indicate minimum detectable concentrations. 
All comparisons are p>0.3 by the Mann-Whitney test except for IL-1β. 
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Figure A1.3. Additional genital cytokines that are higher in CT4 than CT1, including women with 
STIs (A-C) or excluding women with any STIs (D-L). P values in upper left corners were 
determined by a Kruskal-Wallis test, and asterisks denote significance level after post-test. Data 
shown as median with interquartile range. * denotes p < 0.05; ** p < 0.01; *** p < 0.001. 
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Figure A1.4. Genital cervicotypes do not correlate with peripheral CD4+ (A, C) and CD8+ T cell 
(B, D) activation levels. Significance levels were determined by a Kruskal-Wallis test for HLA-
DR/CD38 and an ordinary one-way ANOVA for CD25. 
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Figure A1.5 Longitudinal bacterial abundances and genital cytokine levels. (A-K) Longitudinal 
profiling of cervical bacterial abundances and IL-1α, IL-1β, and TNF-α concentrations in five 
women with fairly constant microbial communities (A-E) and six women with community 
fluctuations (F-K). Cervicotype (CT) designations are shown above each barplot. (L) Table of 
CT transitions between serial time points. 
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Figure A1.6 Correlations of bacterial communities with genital cytokines, and bacterial species 
with one another.  
(A) Heatmap of bacterial taxa identified by 16S V4 sequencing with a second heatmap 
representing matched CVL cytokines: IL-1α, IL-1β, TNF-α, IL-12p70, IL-10, and IL-4. Cytokine 
concentrations were normalized.  
(B) Graphical Spearman correlation matrix of bacterial abundances found in the 94 cervical 
swabs. The areas and colors of circles show the absolute value of the corresponding correlation 
coefficients. Only correlations with p < 0.01 are shown. 
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Figure A1.6 (Continued) 
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Table A1.1. Principal components analysis to reduce cytokine data dimensionality. Loading of 
each variable to the first principal component (explaining 41% of variation) and the second 
principal component (explaining 13% of variation.) 
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Table A1.2. Demographics, sexual behavior, and progesterone levels in women in the top and 
bottom quartile of cytokine PC1. Women in the top quartile of cytokine PC1 had older current 
partners (1.91 year difference in means, P = 0.0103). Data shown as median with interquartile 
range or mean with standard deviation. 
 
    Low PC1 High PC1 Significance 
 Age of sexual debut 18 [17, 19] 18 [17, 19] p = 0.9879 
a 
 Age of first sexual partner 21 [19, 22] 21 [20, 22.5] p = 0.2986
 a 
 Age of oldest sexual partner 26 [23, 27] 26 [24, 28] p = 0.4199 
b 
 Age of current sexual partner 23 [21, 26] 26 [23.5, 28] p = 0.0103 
b 
     
 Days since last sex episode 13 [4, 42] 12 [5.75, 42] p = 0.9528 
b 
 Number of sex acts in last 7 days 0 [0, 1] 0 [0,1] p = 0.8735 
b 
 Number of sex acts in last 30 days 2 [0, 4] 2 [0,4] p = 0.8619 
b 
     
 Blood progesterone level (ng/ml) 
0.15 [0.1, 
0.5] 0.1 [0.1, 0.2] p = 0.4008 
b 
     
    Low PC1 High PC1 Significance c 
  No sex partners in last 7 days 16 12 
p = 0.2167 
 1 or more sex partners 15 22 
     
 No casual sex partners in last 7 days 31 34 p = 1 
 1 or more casual sex partners 0 0  
     
 No oral sex 28 31 p = 1 
 Oral sex reported 2 2 
     
 Always used condoms in past 30 days, or no sex 9 12 
p = 0.553  Sometimes used condoms 12 11 
 Never used condoms 6 11 
     
 No family planning 19 15 p = 0.2162 
 Using family planning 12 19 
     
 No STI history 27 23 p = 1 
 STI history 7 7 
     
 No STI symptoms 30 32 p = 1 
  STI symptoms 1 2 
     
 
a Unpaired T test 
   
 
b Mann-Whitney Test 
   
 
c Fisher’s exact test 
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Table A1.3. Metadata from thirteen participants with longitudinal 16S profiling and 
cervicovaginal lavage measurements. Abbreviations: Cervicotype (CT), oral contraceptive pill 
(OCP). 
 
 
Days 
from 
baseline CT 
STI 
PCR BV 
# Sex 
episodes 
in 7 days 
Days 
since 
last sex 
episode 
# anal 
sex 
episodes 
in last 30 
days 
Condom 
use in last 
30 days 
History 
of STIs 
(self-
reported) 
 STI 
symptoms 
now (self-
reported) 
Family 
planning 
(FP)  method 
Participant 12 0 4 ------ 6 0 14 0 Always No No IUD 
Participant 12 98 4 ------ n/a 0 16 0 Always No Yes IUD 
Participant 12 186 4 ------ n/a 1 1 0 Always No No IUD 
Participant 12 249 4 NG+ 7 1 2 0 Never No No IUD 
Participant 13 0 3 ------ 0 2 5 0 Sometimes No No Depoprovera 
Participant 13 87 2 ------ 1 2 7 0 Sometimes No No Depoprovera 
Participant 13 178 2 ------ n/a 2 3 0 Sometimes No No Depoprovera 
Participant 13 269 2 ------ 1 n/a n/a n/a n/a n/a n/a Depoprovera 
Participant 13 335 2 ------ 0 0 12 0 Sometimes No No Depoprovera 
Participant 14 0 2 ------ 0 1 7 0 Sometimes No No No FP 
Participant 14 81 2 n/a n/a 3 4 0 Never No No No FP 
Participant 14 179 4 ------ n/a 1 3 0 Never No No No FP 
Participant 14 227 4 NG+ 1 1 6 0 Never No No No FP 
Participant 15 0 1 ------ 0 1 7 0 Never No No Nuristerate 
Participant 15 168 2 ------ n/a 1 4 0 Never No No Nuristerate 
Participant 15 245 2 ------ 1 4 3 10 Never No No Nuristerate 
Participant 15 329 2 ------ 1 4 2 0 Sometimes Yes No Nuristerate 
Participant 16 0 4 ------ 9 0 60 0 Sometimes No No No FP 
Participant 16 171 4 ------ n/a 0 53 0 n/a No No No FP 
Participant 16 245 4 ------ 6 0 26 0 Always No No No FP 
Participant 16 329 4 ------ n/a 0 8 0 Never No No No FP 
Participant 17 0 n/a TV+ 3 1 6 0 Always No No OCP 
Participant 17 88 4 n/a n/a 1 7 0 Sometimes No No OCP 
Participant 17 179 4 HSV2+ 9 1 4 0 Never No No OCP 
Participant 17 227 4 n/a n/a 5 2 0 Sometimes No No OCP 
Participant 18 0 2 ------ 1 0 15 0 Sometimes No No No FP 
Participant 18 81 4 n/a n/a 1 6 0 Sometimes No No OCP 
Participant 18 258 3 CT+ 1 0 45 n/a n/a No No OCP 
Participant 19 0 3 ------ 6 2 3 0 Sometimes No No Nuristerate 
Participant 19 171 3 ------ n/a 0 17 1 Never No No No FP 
Participant 19 259 4 ------ 9 0 34 n/a n/a n/a No No FP 
Participant 19 337 4 ------ n/a 0 17 0 Sometimes No No No FP 
Participant 20 0 1 ------ 0 1 7 0 Sometimes No No No FP 
Participant 20 172 2 ------ 1 0 22 0 Sometimes No No No FP 
Participant 20 266 3 ------ 1 0 18 0 Sometimes No No No FP 
Participant 21 0 2 ------ 0 1 6 0 Sometimes Yes No Depoprovera 
Participant 21 81 4 ------ 3 1 4 0 Sometimes No No No FP 
Participant 21 186 3 ------ n/a 1 4 0 Never No No No FP 
Participant 21 263 4 ------ 9 0 30 0 Never No No No FP 
Participant 21 333 4 NG+ 6 0 16 0 Sometimes No No No FP 
Participant 22 0 1 ------ 1 1 6 0 Never No No No FP 
Participant 22 98 2 ------ n/a 1 5 0 Never No No No FP 
Participant 22 182 1 ------ n/a 3 1 0 Sometimes No No No FP 
Participant 22 241 1 NG+,CT+ 2 1 3 0 Never No No Nuristerate 
Participant 23 0 2 ------ 2 0 30 0 Never Yes No Depoprovera 
Participant 23 84 1 n/a n/a 0 60 0 n/a No No Depoprovera 
Participant 23 171 2 ------ n/a 0 30 0 Sometimes No No Depoprovera 
Participant 23 230 2 ------ 1 0 60 n/a n/a No No Depoprovera 
Participant 24 0 4 ------ 8 1 3 5 Never No No No FP 
Participant 24 94 4 ------ n/a 0 27 0 Sometimes No No No FP 
Participant 24 182 4 ------ n/a 0 9 0 Never No No No FP 
Participant 24 240 4 ------ 6 1 4 1 Sometimes No Yes No FP 
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Figure A2.1 Expanded heatmap from Figure 3.2 displaying Gardnerella dominant communities 
as well. No difference in peripheral blood antigen presenting cells from women with different 
genital bacterial communities. The heatmap displays only genes that were significantly 
differentially expressed in cervical antigen presenting cells.  
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Table A2.1. Spearman correlations between individual bacteria and cytokine PC1. 
 
Parameter 
Spearman 
r 
95% confidence 
interval 
P value (two-
tailed) 
Prevotella 0.4443 0.2588 to 0.5982 < 0.0001 
Mycoplasma 0.4781 0.2985 to 0.6251 < 0.0001 
Other (unassigned) 0.5134 0.3404 to 0.6528 < 0.0001 
Gemella 0.5234 0.3525 to 0.6606 < 0.0001 
Fusobacterium 0.3882 0.1944 to 0.5528 0.0001 
Leptotrichiaceae 0.3911 0.1977 to 0.5552 0.0001 
Lactobacillus iners -0.3585 -0.5284 to -0.1610 0.0004 
Sneathia 0.3504 0.1520 to 0.5217 0.0006 
Aerococcus 0.3445 0.1454 to 0.5168 0.0007 
Clostridiales 0.3422 0.1429 to 0.5149 0.0008 
Mobiluncus 0.3347 0.1345 to 0.5086 0.001 
Lactobacillus (non-iners) -0.2918 -0.4725 to -0.08760 0.0045 
Arcanobacterium 0.2628 0.05625 to 0.4477 0.0109 
Atopobium vaginae 0.2471 0.03951 to 0.4342 0.017 
Veillonella 0.2279 0.01917 to 0.4175 0.028 
Porphyromonas 0.1957 -0.01449 to 0.3893 0.0601 
Peptostreptococcus 
anaerobius 0.1733 -0.03764 to 0.3695 0.0966 
Lactobacillus reuteri -0.1455 -0.3446 to 0.06609 0.164 
Prevotella intermedia 0.143 -0.06868 to 0.3423 0.1715 
Gardnerella 0.107 -0.1049 to 0.3097 0.3071 
Prevotella melaninogenica 0.1022 -0.1097 to 0.3053 0.3296 
Shuttleworthia 0.08394 -0.1279 to 0.2885 0.4238 
Megasphaera 0.07931 -0.1325 to 0.2842 0.4498 
Prevotella copri -0.05216 -0.2589 to 0.1592 0.6195 
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Table A2.2. Bacterial pathways identified by HUMAnN to be differentially abundant between 
women with high versus low genital inflammation. 
KEGG Pathway Enriched in: 
LDA 
Score 
(Log 10) 
ko00780| Biotin metabolism HighInflamm 3.290 
ko00540| Lipopolysaccharide biosynthesis HighInflamm 3.201 
ko00750| Vitamin B6 metabolism HighInflamm 3.157 
ko00410| beta-Alanine metabolism HighInflamm 3.149 
ko02040| Flagellar assembly HighInflamm 3.110 
ko02030| Bacterial chemotaxis HighInflamm 3.088 
ko00523| Polyketide sugar unit biosynthesis HighInflamm 3.042 
ko05310| Asthma HighInflamm 3.042 
ko00660| C5-Branched dibasic acid metabolism HighInflamm 2.986 
ko00860| Porphyrin and chlorophyll metabolism HighInflamm 2.915 
ko00340| Histidine metabolism HighInflamm 2.885 
ko00260| Glycine, serine and threonine metabolism HighInflamm 2.871 
ko00361| Chlorocyclohexane and chlorobenzene 
degradation HighInflamm 2.850 
ko00330| Arginine and proline metabolism HighInflamm 2.715 
ko05131| Shigellosis HighInflamm 2.525 
ko00562| Inositol phosphate metabolism HighInflamm 2.490 
ko05120| Epithelial cell signaling in Helicobacter pylori 
infection HighInflamm 2.311 
ko02060| Phosphotransferase system (PTS) LowInflammation 3.503 
ko03430| Mismatch repair LowInflammation 3.227 
ko00240| Pyrimidine metabolism LowInflammation 3.221 
ko00051| Fructose and mannose metabolism LowInflammation 3.215 
ko00072| Synthesis and degradation of ketone bodies LowInflammation 3.112 
ko00052| Galactose metabolism LowInflammation 3.100 
ko00520| Amino sugar and nucleotide sugar metabolism LowInflammation 3.060 
ko00230| Purine metabolism LowInflammation 2.962 
ko00010| Glycolysis / Gluconeogenesis LowInflammation 2.903 
ko00561| Glycerolipid metabolism LowInflammation 2.865 
ko03020| RNA polymerase LowInflammation 2.794 
ko00621| Dioxin degradation LowInflammation 2.728 
ko05150| Staphylococcus aureus infection LowInflammation 2.640 
ko02010| ABC transporters LowInflammation 2.603 
ko04662| B cell receptor signaling pathway LowInflammation 2.331 
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Figure A3.1 Concentrations of cytokines in cervicovaginal lavages among naturally cycling women in the 
follicular phase (n=33) or luteal phase (n=16) of the menstrual cycle,  or women using DMPA (n=41) or 
NET-EN (n=10).  
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